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Abstract
The human adenovirus (HAdV) E1A protein is the first protein produced post-HAdV
infection, and serves two main functions. The first is to modulate host and viral transcription.
The second is to induce host cell cycle progression to S phase, to promote an optimal
environment for viral replication. E1A performs its functions by binding and manipulating
over 50 cellular factors. Interestingly, I found that E1A is capable of interacting with the
poorly characterized human DNA replication-related element-binding factor (hDREF).
hDREF is a transcription factor involved in the expression of several genes related to the cell
cycle. I hypothesized that the interaction between E1A and hDREF would contribute to
adenovirus induced transcriptional modulation and viral replication in HAdV-5 infected host
cells.
Utilizing co-immunoprecipitation experiments, I discovered that E1A can bind hDREF
through residues 15-26. Using quantitative real time polymerase chain reaction (RT-PCR), I
found that hDREF also increases expression of HAdV-5 E3 and E4 genes, which are transactivated by E1A. Finally, hDREF expression increases HAdV-5 replication. Further studies
will reveal whether or not the E1A-hDREF interaction is specifically responsible for these
observed results.
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Introduction

1.1

Adenoviruses

Adenoviruses (AdV) – named for their discovery in human adenoid tissue – were first
isolated and characterized by two independent groups in 1953, who were searching for
the causative agent of acute respiratory disease (ARD) plaguing military recruits during
World War II (1–3).

It is now known, however, that human AdVs (HAdVs) are

responsible for only 5-10% of upper respiratory tract disorders in children, and that
rhinoviruses are the major causative agents behind the common cold (4, 5). HAdVs have
since been confirmed as the etiological agents of many other clinical diseases, most
notably conjunctivitis and infantile gastroenteritis (6–8). Although most infections are
self-limiting and can be asymptomatic, immunosuppressed patients may experience fatal
infections arising through pneumonia, encephalitis, and fulminant hepatitis (9).
The Adenoviridae family contains over 100 members spanning five genera, which infect
a range of vertebrates from fish to humans (10). All HAdVs are classified within the
genus Mastadenovirus, which comprises those viruses isolated from mammals (11).
There are currently 57 accepted HAdV comprising six species (A-F), with a purported
seventh species (G) containing only serotype 52 (12, 13) (Table 1.1). Classification of
HAdV into species and serotypes is complicated. Species are classified based on their
ability to agglutinate red blood cells, as only antisera against viruses of the same species
will prevent the hemagglutination reaction (14). New serotypes are denoted based on the
ability of the virus to resist neutralization by antisera against known HAdV types (15).
This mainly occurs via exposed virion hexon proteins, as hypervariable regions exist on
the hexon surface which are type-specific (16–18). Therefore, individual HAdV types
will only neutralize themselves.
The use of HAdVs as experimental models initially became evident in 1962 when Trentin
et al. discovered that injection of HAdV-12 of species A into infantile hamsters caused
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malignant tumors (19). He provided the first recorded evidence of a human virus causing
oncogenesis. Only certain species of HAdVs are oncogenic, as tumorigenicity is closely
linked to the ability of individual serotypes to evade the host immune system. Indeed, all
species can promote tumorigenesis in immune-compromised rodents (20). Furthermore,
all species can transform cultured rodent cells, establishing HAdVs as useful model
systems for studying the mechanisms of cancer (21). Currently, no HAdVs have been
implicated in the oncogenesis of human tumors (22, 23). HAdV infections in rodents are
non-productive due to a deficiency in both viral DNA replication and late protein
production (24). In contrast, HAdV infections in humans are lytic, and therefore cell
death occurs long before tumorigenesis could occur. However, E1A is capable of
immortalizing human cells on its own when stably transfected, and in cooperation with a
second oncogene such as E1B, can fully transform human cells (25, 26). Human
embryonic kidney (HEK) 293 cells were transformed in such a fashion, but
transformation of other cell lines with E1A and other oncogenes has proven difficult (25).
Since 1962, the use of HAdVs as molecular tools has gained popularity due to several
enticing characteristics. HAdVs are easily grown to high titres, unlike other tumor viruses
with more stringent growth conditions, such as human papillomavirus (HPV) (27). They
cause synchronous infections in cultured cells, allowing the kinetics of infections to be
easily studied and replicated (21). The genomes of many HAdVs are well characterized
and easily manipulated, facilitating the study of the functions of both HAdV gene
products and the cellular factors that interact with them (4). HAdVs have played a large
role in our understanding of DNA replication, cell cycle control, transcription, apoptosis,
immunological responses to viral infections, and mRNA processing (21). For example,
the discovery that multiple mRNAs are produced from a single transcript – a process we
now know as mRNA splicing – as well as the discoveries of introns and pre-mRNA
processing to mature mRNA, are all credited to the studies of HAdV infected cells (28–
32).
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Table 1.1 Classification of Human Adenoviruses
Species

Serotypes

Tumorigenicity in
Rodents

Transformation of
Cell Culture

A

12, 18, 31

High

Yes

B

3, 7, 11, 14, 16, 21, 34,
35, 50, 55

Moderate

Yes

C

1, 2, 5, 6, 57

Low or None

Yes

D

8, 9, 10, 13, 15, 17, 19,
20, 22-30, 32, 33, 3639, 42-49, 51, 53, 54,
56

Low or None

Yes

E

4

Low or None

Yes

F

40, 41

Unknown

Yes

G

52

Unknown

Unknown

Adapted from Berk, AJ., 2007 (4)
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1.1.1

HAdV Virion Structure

All HAdV are 90nm diameter, icosahedral, non-enveloped particles with fibres
protruding from each vertex of the virion (33) (Figure 1.1). The virions are made up of a
proteinacious capsid surrounding a core which contains the DNA genome. There are 11
proteins in the virion named/numbered II-IX, IIIa, terminal protein, μ, and p23 viral
protease (34). 240 hexon capsomers – which are trimers of polypeptide II – comprise the
20 faces of the virion, with 12 hexons on each face (35). 12 penton capsomers – which
are comprised of a penton base made of a pentamer of polypeptide III, and a projecting
fibre made of a trimer of polypeptide IV – form the vertices of the icosahedron (36). The
fibre contains three major domains: the N-terminal domain contains an invariant
FNPVYPY motif found in all HAdV fibres, which connects the fibre to adjacent penton
base monomers; a central shaft of 6 to 22 repeating units of a 15-residue motif which
forms a “triple β-spiral” fold; and a C-terminal knob domain, which contains a binding
site for HAdV receptors on host cells (34, 36–39). Together the flexibility of the shaft
and the specificity of the knob domain act as major determinants of viral tropism. The
coxsackievirus and AdV receptor (CAR) – a transmembranous immunoglobulin
superfamily member found on a vast array of cell types – was discovered as the main,
high-affinity receptor for serotypes 2 and 5 of species C (40, 41). It has also been
implicated as a main receptor of species A, D, E, and F but not B, as the knob domain in
species B is highly divergent in sequence (42, 43). In addition, deviations may occur on
an individual basis in each species, as is evidenced by HAdV-37 of species D, which
cannot efficiently use CAR as a receptor due to a rigid shaft domain, and instead utilizes
sialic acid as a receptor (44, 45). Although most HAdV encode only a single type of
fibre, HAdV-40 and -41 of species F encode a second fibre with an unknown receptor
which may be responsible for their increased tropism for intestinal cells (46–48).
Several minor capsid proteins stabilize protein-protein interactions in the virion.
Polypeptides VIII and IX stabilize hexon-hexon interactions (34). Four trimers of IX act
as a sort of molecular adhesive to keep the nine central hexons of each icosahedral face in
a single plane, promoting virion stability (49–51). Protein IIIa is important for virion
assembly, interacting under the capsid with the penton base at each vertex as well as the

5

Figure 1.1 Cartoon diagram of HAdV virion. A) Enlarged diagram of one icosahedral
facet (dark blue triangle), displaying the 12 hexon and 3 penton capsomers as well as the
approximate locations of other minor structural proteins that support the major capsid
proteins. B) Predicted locations and arrangement of structural proteins and DNA within
the core of the capsid (TP = terminal protein; AVP = AdV protease). Adapted from San
Martin, C., 2012 (52).

6
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Figure 1.1 Cartoon diagram of HAdV
virion
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surrounding hexons of each face, essentially holding them together as a scaffold (34, 53,
54). Minor protein VI mediates destruction of the endosomal membrane during
internalization, after the capsid has disassembled, and it serves a structural function by
tethering the capsid to the protein-DNA core of the virion (39, 55).
Five proteins as well as the DNA genome comprise the virion core. Polypeptides V, VII,
and μ are highly basic proteins which contact and condense the viral DNA within the core
(56–58). The major core protein is polypeptide VII, which forms dimers that condense
the viral DNA into repeating 90-150 base pair nucleoprotein complexes (59, 60). In
addition to binding DNA, polypeptide V can bind the penton base and polypeptide VI,
participating in the linkage of the core to the capsid (61). The terminal protein is
covalently attached to the 5’ ends of the viral genome, functioning in DNA replication as
a primer for DNA synthesis (62). Finally, the p23 viral protease cleaves several proteins
to allow escape from endosomes during infection, as well as several precursors of viral
proteins during maturation of the virions (63, 64).

1.1.2

HAdV Genome

Many HAdV genomes have been completely sequenced to date, the first of which were
those of HAdV-2, 5, and 12 (65–67). All contain approximately 36000 bp of linear,
double-stranded DNA. The genome encodes five early (E1A, E1B, E2 early, E3, E4),
three delayed-early (IX, IVa2, E2 late), and one major late transcriptional unit which are
transcribed by cellular RNA polymerase II (68). Each of these transcripts is alternatively
spliced, giving rise to multiple mRNAs (Figure 1.2). Furthermore, many alternatively
spliced products of an individual transcriptional unit encode proteins with similar
function. For example, two major E1A proteins – 13S and 12S – activate transcription of
HAdV genes and force cells into S phase, and the late transcriptional units encode
proteins involved in capsid production and assembly (4). The genome also encodes virusassociated RNAs (VA-RNAs) which are transcribed by RNA polymerase III (10). The
ends of the genome contain inverted terminal repeats of 36 to over 200bp, which function
as origins of replication (ORI) for DNA synthesis (10). Cis-acting packaging sequences
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are present between the left terminal repeat and the E1A-coding region, and are essential
for proper packaging of replicated DNA into new virions (69, 70).
The genomes of the closely related HAdV-2 and 5 have been extensively manipulated to
create viruses which express proteins containing one or more mutations (71). As such,
most studies utilize one of these serotypes for studies, including our laboratory which
focuses on the study of HAdV-5. By utilizing the natural homologous recombination
machinery of Escherichia coli, plasmids containing the entire genome of HAdV-5 with
mutations of interest can be constructed (72). Plasmids can be amplified to large
quantities, isolated, and transfected into HEK 293 cells, which express HAdV-5 E1A and
E1B (25). Through transcription of viral genes and replication of viral DNA, viral
progeny are created which lyse the cells, and can be plaque purified by further
propagation in 293 cells. Many mutant viruses are not as viable as wild type HAdV-5 and
thus the complementation of E1A and E1B in 293 cells – particularly for those with
mutations in E1A or E1B – serves to increase viral production. In fact, the dl312 (ΔE1A)
strain of HAdV-5 – a common control virus for studying effects of E1A – grows as well
as wild-type in these cells, whereas it cannot replicate efficiently in HeLa cervical
carcinoma cells (73). Viruses purified from 293 cells can then be used to examine the
effects of specific mutations on cellular and viral processes in cells of interest.

1.1.3

HAdV Replication Cycle in Human Cells

Like all viruses, HAdV are obligate intracellular pathogens and therefore must infect a
host cell and manipulate the cellular machinery in order to replicate. Most studies of
HAdV replication have traditionally been carried out in HeLa cells or their derivatives at
high multiplicities of infection (MOI), ranging from 10 to over 200 plaque forming units
(PFU) per cell (4, 73–76). HAdV grows very rapidly in these cells, and a high MOI
ensures that all cells undergo synchronous infection, enabling the observation of
consistently ordered events over time. In contrast, the replication cycle in primary cells,
such as IMR-90 lung fibroblasts, is drastically slower (77, 78).

9

Figure 1.2 Transcription map of HAdV-5 genome. Genes are transcribed from both
strands of the genome. Arrows indicate direction of transcription. Breaks in arrows
indicate mRNA splice sites. Protein names are indicated above or below their respective
coding mRNA. An untranslated tripartite leader sequence indicated by the labels 1, 2, and
3 is spliced onto mRNA transcribed from the major late promoter (MLP). The labelled
“i” indicates a leader sometimes transcribed and spliced onto the 52/55K L1-mRNA,
which produces a unique but nonessential 13.6kd protein. Adapted from Berk, AJ., 2007
(4).

10

Figure 1.2 Transcription map of HAdV-5 genome
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In general, the HAdV replication cycle exhibits an early phase and a late phase, which are
separated by the initiation of viral DNA replication (68). Adsorption, entry, uncoating,
translocation of viral DNA to the nucleus, and expression of early genes comprise the
early phase. At an MOI of 10 in HeLa cells, DNA replication initiates at around six hours
post-infection (HPI), at which point the late phase begins and late genes are expressed.
This culminates in the production and release of virions, completing the lytic cycle at 24
to 36 HPI (79) (Figure 1.3). At high MOIs, infected cells are completely killed, and thus
no further cycles of viral replication can be observed. It is important to note that although
early and late phases are convenient categorizations of replicative events, they are not
definitive time-points. The major late transcriptional unit is transcribed at low levels in
the early phase, the delayed-early genes are expressed intermediately in infection, and the
early genes continue to be expressed during the late phase (68).

1.1.3.1

Adsorption, Internalization, Uncoating and Nuclear Import

The information pertaining to viral replication in the proceeding subsections of 1.1.3 will
focus on HAdV-2 and 5 – which are 95% homologous at the genomic level – as
replication of other serotypes mimic these two prototypes (4, 65). The DNA encoding for
the fibre protein accounts for 50% of the differences in HAdV-2 and 5, although both
serotypes utilize the same receptor.
Attachment to the CAR is mediated by the knob domain of the fibre protein (80, 81). The
receptor is abundantly expressed at epithelial cell tight junctions in most tissues (82, 83).
After attachment the penton capsomers at the base of the fibre bind to type a vβ3 and avβ5
integrins through a conserved RGD motif found on the surface of each penton monomer
(84). This causes detachment of the fibre, and promotes integrin clustering and activation,
leading to downstream signalling of the phosphatidylinositol-3-OH kinase (PI3K)
pathway (85, 86). The signalling pathway culminates in actin rearrangement, enabling
endocytosis of a fibre-less virion via clathrin-coated vesicles (87–89).
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Figure 1.3 HAdV-5 replication cycle in human cells. HAdV binds to the CAR receptor
(horseshoe) via the knob domain of the fibre protein (1). Integrin (boxhead) binding and
clustering stimulates receptor-mediated endocytosis (2, 3). Viral uncoating begins to
occur as the subviral particle is released from acidified endosomes. The HAdV genome is
shuttled to the nuclear pore complex (NPC) on microtubules, where final uncoating
occurs as the genome is translocated into the nucleus (4). Early viral gene expression
begins, and the host cell is forced into the cell cycle. Next DNA replication and late gene
expression begins (5, 6). Viral proteins localize back into the nucleus, where they
assemble with the viral genome into virions (7). Cell lysis occurs and new infectious
HAdV virions are released (8).
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It is currently accepted that clathrin-coated vesicles mature into endosomes, and become
acidified. Acidification triggers permeabilization of the membrane and enables
translocation of the virus to the cytosol (90–92). However, the mechanisms surrounding
this process are not completely understood. In some studies it has been shown that a low
pH endosomal environment is not required during an in vivo infection (93). The entire
process of attachment, internalization, and escape from endosomes is very rapid, and
occurs within 15 minutes of initial attachment (94). Partial uncoating of the viral capsid
occurs concurrently with endosomal release, and then hexon proteins utilize cellular
microtubules to shuttle the subviral core to nuclear pore complex (NPC) (80, 95, 96). At
this point – approximately 2 HPI – the remaining proteins of the capsid disassemble at
the NPC, and the viral DNA bound to major core protein VII is imported into the nucleus
(97).

1.1.3.2

Transcription and Function of Early Genes

Early HAdV gene products are responsible for activating transcription of viral genes,
inducing host cell cycle progression, initiating viral DNA replication, and blocking
apoptosis and host anti-viral responses (4). The E1A transcriptional unit contains a
constitutively active enhancer, and is the first viral gene expressed during infection (75,
98). E1A gene products are the primary trans-activators of the viral genome, and thus the
functions of other early genes intimately depend on E1A. Due to the multiple and
important functions of E1A, it will be discussed in detail in section 1.1.4.
The E1B transcriptional unit encodes two proteins identified by their molecular weights
of 55 and 19kDa. They function to inhibit apoptosis, which would otherwise occur in
response to the abnormal cell cycle progression induced by E1A and E4orf4 (99). E1B55k uses several distinct mechanisms to inhibit E1A-induced p53 tumour suppressor
trans-activation of genes involved in apoptosis and cell-cycle arrest. In cooperation with
E4orf6 and cellular proteins, E1B-55k forms a large 800kDa ubiquitin ligase complex
which binds p53, directing its polyubiquitination and consecutive proteosomal
degradation (100–103). E1B-55k on its own can also bind p53 at genes containing p53-

15

binding sites, functioning to repress these genes (104, 105). E4orf4 induces p53independent apoptosis through proteosomal degradation of the cellular antiapoptotic
MCL-1 protein (106). E1B-19k acts as a viral MCL-1 mimic, which binds BAX and
BAK, preventing mitochondrial outer membrane pore formation and release of
cytochrome c, thereby inhibiting apoptosis (107).
The E2 transcriptional unit encodes three proteins involved in viral DNA replication: The
terminal protein (TP), a 140kDa DNA-dependent DNA polymerase (AdDdDp) of the
eukaryotic polymerase-α family, and a 59kDa single stranded DNA (ssDNA) binding
protein (ssDBP) (108–110). The TP is post-translationally processed and covalently
attached by AdDdDp to the first base – deoxycytidine monophosphate – at either of the
5’ ends of the viral genome (111, 112). The TP functions to separate double-stranded
DNA (dsDNA) at the ORI, allowing docking of the template strand into AdDdDp, for
which TP then acts as a primer (112, 113). Like all DNA polymerases, AdDdDp contains
5’ to 3’ DNA polymerase activity, and like other polymerase-α family members, it
contains 3’ to 5’ exonuclease activity for proofreading of DNA synthesis (114, 115). The
ssDBP functions in chain elongation, driving strand separation through its polymerization
on DNA, and replacing the function of DNA helicase in unwinding dsDNA (116). The
ssDBP increases the processivity of AdDdDp, allowing complete strand synthesis
without re-docking and re-initiation.
The E3 transcriptional unit encodes proteins involved in antagonizing the adaptive
cytotoxic T lymphocyte (CTL) response, and the innate apoptosis-inducing cytokine
response (117). These include: E3-19K, 14.7K, 14.5K, 10.4K, 6.7K, and adenovirus
death protein (ADP/E3-11.6K). E3-19K is a transmembrane protein that localizes to the
endoplasmic reticulum (ER) in infection (118). It binds the major histocompatibility
complex (MHC) class I peptide-binding groove and through an ER-retention signal,
prevents MHC class I from reaching the surface of the host cell (119, 120). In addition it
can bind TAP – a protein which loads processed cytosolic peptides onto the MHC class I
molecule in the ER – and prevent MHC class I peptide docking (121). Since lysis of an
infected cell by CTLs requires antigen presentation, E3-19K can effectively inhibit
adaptive immunity. Two E3-10.4K and one E3-14.5K comprise the viral transmembrane
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receptor internalization and degradation (RID) complex, which causes endocytosis and
subsequent lysosomal degradation of the Fas (CD95) and tumor necrosis factor (TNF)related apoptosis-inducing (TRAIL) receptors (122–124). These receptors bind Fas ligand
on CTLs and TRAIL cytokines secreted by immune cells and subsequently induce
apoptosis, and therefore degradation protects from cell death. The transmembrane E36.7K protein assists the RID complex in protection against Fas ligand and TRAIL, as well
as TNF-α (124, 125). The E3-14.7K protein is found in the cytosol, and inhibits TNF-α,
TRAIL, and Fas ligand-induced apoptosis by binding the downstream FLICE caspase and
inhibiting its function (126–128). It can also bind members of the IκB kinase (IKK)
complex, blocking nuclear factor kappa B (NF-κB) activation, and preventing expression
of several TNF-α induced chemokines important for immune chemotaxis (129). Contrary
to the other E3 proteins, ADP is expressed late during infection (130). It contributes to
lysis of cells as it accumulates, through a currently unknown mechanism (131).
The E4 transcriptional unit encodes proteins with a wide array of functions, which are
named after their respective genomic open reading frames (ORFs). As previously
discussed, E4orf6 cooperates with E1B-55k to inhibit p53-dependent apoptosis, but can
also inhibit p53-dependent transcription independently (132). In addition, the
E4orf6/E1B-55k 800kDa complex and E4orf3 act to prevent the cellular DNA damage
response pathway from acting on the viral genome (133). They function by interfering
with the activity and causing the eventual degradation of Mre11-Rad50-Nbs1 (MRN)
complexes, which would otherwise recognize the ends of linear HAdV genomes as
double-stranded breaks (134). This would result in concatenation of viral genomes by the
nonhomologous-end-joining pathway, preventing proper viral DNA replication and
subsequent packaging (133, 135, 136). Finally, the E4orf6/E1B-55k 800kDa complex
acts to block cellular mRNA export to the cytoplasm, and promote viral late mRNA
export to the cytoplasm through the Nxf1/Tap export receptor after the onset of viral
DNA replication (137–141). This results in the inhibition of cellular protein synthesis,
and promotes viral protein synthesis. E4orf1 and E4orf4 function to activate the protein
kinase mammalian target of rapamycin (mTOR) – and thus translation – through distinct
pathways (142–145). Activation of mTOR normally occurs in response to nutrient and
mitogen signalling, and is required for entry of the host cell into S phase (146). mTOR
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phosphorylates p70S6K which in turn phosphorylates ribosomal protein Small 6 (RPS6),
leading to a high rate of protein synthesis and allowing mRNA of several cell-cycle
regulators such as cyclins to be translated (147–149). Finally, the E4orf6/7 protein binds
the E2F transcription factor, and recruits it to the E2 early promoter to provide E1Aindependent and E1A-cooperative transactivation of E2 genes (150, 151).
HAdV-5 encodes two VA-RNAs – VA-RNAI and VA-RNAII – which are transcribed by
RNA polymerase III in the nucleus and form stable secondary structures important for
their function (152). They act to antagonize host cell viral countermeasures. They are
transcribed in the early phase, and reach extremely high levels in the late phase of
infection. Both types competitively inhibit cellular micro RNA (miRNA) export and also
subsequent processing by Dicer (153, 154). Instead, VA-RNAs are processed by Dicer
and then overwhelm the RNA silencing complexes (RISC), which would otherwise seek
out and degrade viral mRNA (155). Since VA-RNAs are transcribed from intronic
regions in the viral genome, the actions of RISC will only act on subsequently transcribed
VA-RNA genes, with no effect on viral fitness (153). In addition, VA-RNAI binds and
inhibits protein kinase R (PKR), which is synthesized in response to interferon α and β
(IFN-α, IFN-β) production after viral infection (156, 157). Without this antagonization,
PKR would recognize the dsRNA transiently formed by transcription of both strands of
the viral genome, and phosphorylate eukaryotic initiation factor-2-α (eIF-2α), leading to
non-specific inhibition of total protein synthesis (158).

1.1.3.3

DNA Replication, Viral Assembly, and Release

Viral genome replication begins when enough E2-encoded proteins have been
synthesized to support DNA synthesis. In HeLa cells infected at an MOI of 10, DNA
replication occurs between 5 to 8 HPI, and continues until the cell is lysed (4).
There are two stages to HAdV DNA replication. The first stage involves replication of a
single parent strand. Replication initiates from either end of the genome at the previously
described terminal repeats, which act as ORIs (10, 159). This process displaces the
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complementary parent strand, and therefore the first stage ends with a dsDNA genome,
and a displaced ssDNA parent strand. The second stage involves replication of the
displaced parent strand, however the AdDdDp requires dsDNA and an ORI for DNA
replication initiation to occur. The inverted terminal repeats present at each end of the
AdV genome alleviate this issue by looping around and basepairing to each other to
create a duplex DNA “panhandle”, which is utilized as an ORI by AdDdDp (159).
The late genes are expressed at the onset of viral DNA replication, and many of the
proteins they encode were discussed at length in section 1.1.1. They encode proteins
involved in virion packaging and assembly (4, 52). Two events are proposed to be
responsible for the delayed transcription of late genes. First, a currently unknown change
in the viral genome occurring only at the onset of DNA replication allows binding of the
USF/MLTF transcription factor to the major late promoter (MLP) (160, 161). Second, the
MLP contains a binding site for a transcription factor encoded by the delayed early gene
IVa2, which acts in cooperation with USF/MLTF to relieve repression of the MLP (162).
Viral structural proteins translocate to the nucleus where final viral assembly occurs (4,
52). Finally, the cell is lysed and at an MOI of 10, around 10,000 viral progeny are
released from a single HeLa cell (79).

1.1.4

HAdV E1A Functions and Interactions with Cellular Factors

As discussed, E1A is the first viral gene expressed during infection and is essential for
viral replication (75, 163). The various E1A proteins modulate viral and cellular
transcription, induce host cell cycle progression to S phase to create an optimal
environment for viral replication, and inhibit host anti-viral responses through a variety
of intricate mechanisms.
The E1A gene encodes five proteins, termed 9S through 13S based on the sedimentation
coefficients of their respective alternatively spliced mRNAs (Figure 1.4). 13S (289
residues) and 12S (243 residues) are the main products expressed early during infection,
and are the best characterized (164). They differ only by a 46 amino acid sequence found
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in 13S but not 12S. 11S, 10S, and primarily 9S are expressed later in infection, however
their functions are not well understood (165). Recently Miller et al. showed that 9S E1A
could independently activate expression of viral genes, and promote HAdV replication,
and that replication was dependent on an interaction of 9S with the S8 component of the
proteasome (77). This is intriguing as only 28 amino acids are common between 9S and
the larger forms of E1A.
The structure of E1A has not been solved, proving a difficult process as it is an
intrinsically disordered protein (166). However, amino acid sequence alignment of 13S
E1A from various serotypes reveals four main conserved regions (CR1-CR4), which are
separated by less conserved regions (167, 168). CR3 – the region unique to 13S –
contains four cysteines predicted to form a zinc-finger domain, although the structure is
still undetermined (164, 169). In addition, residues 16-28 of the HAdV-5 E1A are
predicted to form an amphipathic α-helix (170). E1A proteins undergo extensive posttranslational phosphorylation at several serine residues, although phosphorylation has
little effect on E1A function (171, 172). Finally, a KRPRP nuclear localization sequence
(NLS) is found at the C-terminus of E1A proteins, accounting for their nuclear
localization (173).
Since E1A proteins have no enzymatic or DNA binding ability, they rely on manipulation
of cellular factors to exert their effects (174). The CRs – as well as other areas –
participate in important protein-protein interactions with over 50 cellular factors through
independently acting short linear interaction motifs (LIMs) (166). The identification of
these motifs has been important to HAdV’s use as a molecular tool, as many of these
linear interaction motifs are also found in cellular factors that bind the same proteins as
E1A. Thus, in addition to studying the function of E1A-interacting proteins through
mutational studies, their cellular binding partners can also be elucidated through
bioinformatic searches for proteins containing the same motifs. For example, both the
retinoblastoma tumor suppressor protein (pRb) and the transcriptional co-repressor Cterminal binding protein (CtBP) were discovered via interactions with E1A (175, 176).
The linear motifs LXCXE in CR2, and PLDLS in CR4 – used by E1A for interactions
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Figure 1.4 Diagram of E1A splice products and proteins. A) The primary E1A
transcript is spliced into 5 different isoforms. Boxes indicate coding regions, which are
separated by bent lines representing introns. Numbers indicate amino acids present in the
translated protein. All proteins besides that encoded by the 9S mRNA are translated
within the same reading frames, resulting in identical proteins except for the indicated
deleted regions. The splicing of the 9S mRNA results in a coding region that is translated
in a different frame than the other four isoforms (indicated by the blue box). B)
Alignment of 13S (289R), 12S (243R), 11S (217R), and 10S (171R) proteins and location
of conserved regions (CR) 1-4. 9S does not retain any of the conserved regions.
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with pRb and CtBP respectively – were subsequently identified in cellular factors later
shown to also bind pRb or CtBP (Figure 1.5).

1.1.4.1

Modulation of Viral and Cellular Transcription

E1A modulates transcription of a large portion of the greater than 17000 cellular
promoters it is recruited to during infection (177, 178). Through various interactions with
cellular sequence-specific DNA-binding transcription factors, or the proteins that regulate
them, E1A proteins act as modulators of cellular and viral gene expression (179).
13S E1A is the primary trans-activator at viral early promoters, which all contain TATAboxes as well as upstream binding sites for cellular trans-activators (180, 181). HAdVs
with complete knockout of 13S E1A or mutations in CR3, experience drastically reduced
rates of early gene transcription (73, 182). This is because CR3 functions as a potent
trans-activator by binding the DNA-binding domains of transcription factors at early
HAdV promoters through its C-terminal 10 amino acids, and recruiting transcriptional
regulators through its N-terminal zinc-finger domain (183, 184). CR3 binds the MED23
subunit of the Mediator (MED) complex, recruiting this co-activation complex to
promoters (185, 186). This interaction is essential for CR3 trans-activation, stimulating
the formation of a pre-initiation complex (PIC) – containing RNA polymerase II and the
general transcription factors – on promoter DNA (185, 187, 188). Thus, through
interactions with MED23, CR3 can aid in recruitment of sequence-specific transcription
factors, and complexes essential for initiation of transcription at early viral genes.
Interestingly, CR3 interacts with many other transcriptional activators, such as TATAbinding protein (TBP), and the p300/CREB-binding protein (CBP), but also with
repressors such as GCN5 and BS69, indicating that CR3 modulation of early gene
transcription is complex (189–192). The N-terminus of E1A (residues 1-41) and CR-1
together are also required for optimal early gene transactivation (193, 194). They have
been shown to interact with a variety of trans-activators including histone acetylases
p300/CBP and p300/CBP-associated factor (pCAF), and TBP, as well as repressors such
as the p400 chromatin remodelling complex (166, 195, 196). The exact mechanisms by
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Figure 1.5 Cartoon diagram of several linear interaction motifs in HAdV-5 E1A.
Locations of several LIMs in E1A are denoted by arrows. The sequence of each LIM is
indicated below the respective protein it interacts with. Viral and cellular proteins which
contain a similar LIM as E1A, and are known to interact with the same LIM target, are
listed below the HAdV-5 LIM. Amino acids highly similar to the consensus LIM binding
sequence are shaded in grey. Adapted from Pelka et al., 2008 (166).
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which the N-terminus and CR-1 exert their effects on viral early genes are relatively
unknown.
12S E1A primarily activates transcription at the E2 early promoter, which contains two
E2 transcription factor (E2F)-binding sites (197). It can do so indirectly by freeing bound
E2Fs from Rb family members pRb, p107, and p130 (198). Interestingly, the E2Fs are
named after their involvement at the E2 promoter, and the pRb proteins were originally
identified as E1A-interacting proteins (197, 199). Free E2F subsequently interacts with
the E4orf6/7 dimer as discussed previously, increasing E2F affinity for its binding sites in
the E2 early promoter (150, 151). In addition, cellular genes – including those required
for entry into S phase – containing E2F-binding sites become constitutively activated
when E2F is released (198). The liberation of E2Fs from pRb is an important event
leading to activation of host cell cycling, and therefore will be discussed more in detail in
section 1.1.4.2.
In addition to modulating early gene transcription, and enabling transactivation of E2Fresponsive genes, E1A plays a complex role in modulating expression of other cellular
genes. Simply stated, E1A recruits and is recruited by activators such as p300/CBP, or
repressors such as pRb and CtBP to do so (177, 178). However, its effects are much more
complicated. E1A can be recruited by activators such as p300 to active genes, upon
which it can then recruit repression complexes to turn expression of those genes off (177,
200). The reverse can also occur, leading to activation of previously inactive genes. One
example of this is the interaction of E1A with the CtBP co-repressor. Classically, E1A
interacts with CtBP through a conserved PLDLS motif in CR4 (175). This removes CtBP
from sequence specific transcription factors, relieving repression of cellular genes.
However, CR3 was also recently found to interact with CtBP and through this interaction,
direct itself to CtBP occupied promoters (201). CtBP repression is alleviated through
E1A binding, and the presence of CR3 then likely causes hyper-activation at these
promoters. Although the specific manners in which E1A affects all of its cellular targets
are not known, the result of E1As modulation of transcription is a host cell that is optimal
for viral replication.
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1.1.4.2

Activation of Cell Cycle

The ability of HAdV to stimulate host cell entry into S-phase allows the virus to
productively infect G0-arrested cells found at the sites of infection. It allows for the
efficient synthesis of viral DNA and proteins, and therefore replication. Whereas 13S
plays a larger role in modulating transcription due to CR3, 12S may primarily promote
cell cycling. HAdV mutants expressing only 13S display drastic reductions in viral
replication in G0-arrested cells, owing largely in part to reduced viral DNA synthesis (82,
202).
E2F transcription factors exist as heterodimers of either DP-1 or DP-2 and one of several
E2F subunits. They regulate transcription of genes essential for cell cycle progression,
such as: DNA polymerase α, cyclin dependent kinase (CDK) 2, cyclin A, and cyclin E
(203). pRb proteins directly bind most E2Fs, repressing E2F activation by recruiting
histone deacetylase and methyltransferase complexes to E2F-responsive promoters and
inhibiting formation of the PIC (204–206). This effectively keeps cells in G0/G1. In
response to extracellular division signals and mitogens, the G1 CDKs (cyclin D-CDK4/6
and cyclin E-CDK2) normally phosphorylate and inactivate pRb, relieving E2Fdependent gene repression, and facilitating entry into S phase (205). Both 13S and 12S
E1A can bind pRb through CR1, and more importantly, through an LXCXE motif in CR2
(4). This motif binds to the Rb “pocket” domain to displace E2F, bypassing the normal
cell cycle regulatory signals, and thereby forcing cell entry into S-phase due to
constitutive activation of E2F-responsive promoters (198, 207). The interaction between
E1A and pRb was the first example discovered of an oncoprotein interacting with a
tumour-suppressor (199). Besides direct binding to pRb, E1A can antagonize CDK
inhibitory proteins (CKI) such as p21, which help to keep the cell in G1 (208). This
results in overactive CDKs and thus hyperphosphorylated pRb, which cannot inhibit E2F
function. Finally, it was recently shown that E1A can bind to E2F complexes
independently of pRb through DP-1, and cooperate with E2F in transactivation of E2Fresponsive genes to force cells into S-phase (78).
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E1A mutants unable to bind pRb still retain the ability to induce an S-phase transition in
host cells, through the N-terminus/CR-1, and therefore other known and unknown targets
of E1A must be influencing host cell cycling (195, 209). Recently it was found that the
N-terminus/CR1/CR3 interacting protein p300 is removed by E1A from promoters of
genes involved in differentiation, and re-directed to promoters involved in the cell cycle
(177, 178). Since p300 is an activator that causes local hyperacetylation, the interaction
may contribute to expression of genes involved in the G1-to-S-phase transition (210).
Although we have a generally good idea as to how E1A activates the cell cycle, there are
still many potentially unknown targets of E1A that may play a role in this process.

1.1.4.3

Subversion of the Host Anti-Viral Response

Although the main functions of the E1A proteins are to modulate viral and cellular
transcription, and induce host cells to enter the cell cycle, it is important to note that E1A
can also antagonize anti-viral responses. For instance: early after infection, E1A binds the
signal transducer and activator of transcription 1 (STAT1) transcription factor through
the N-terminus/CR1, blocking its function (211). STAT1 normally binds to p300/CBP
and IFN-regulatory factor 1 (IRF1) in response to IFN-α and β signalling due to viral
infection (212). This interaction results in expression of anti-viral IFN-stimulated genes
(ISGs) such as PKR (213). Therefore E1A attempts to preclude the production of antiviral factors by blocking IFN signalling. In addition, our lab recently showed that E1A
can bind the human Brefeldin A sensitivity 1 (hBre1) ubiquitin ligase and prevent its
monoubiquitination of histone 2B (H2B) (214). This modification is necessary for
expression of ISGs, and therefore E1A subverts ISG production. Furthermore, Fonseca et
al. revealed that E1A re-directs hBre1 from cellular promoters to viral promoters, and
utilizes it to recruit human polymerase II-associated factor 1 (hPaf1) – an RNA
polymerase II elongation factor – which increases transcription from viral early genes
(215).
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1.2

Discoveries in Drosophila – an Essential Model

System
Since the early 1900’s Drosophila melanogaster has played a central role in our
understanding of the fundamentals of biological processes, particularly at the genetic and
molecular level (216). As a small multicellular organism with a short life cycle, rapid
reproduction schedule, and development stages which parallel those of humans,
Drosophila acts as an appropriate model system for scientific discovery (216, 217). For
example, T. H. Morgan and his students – the first to consider use of Drosophila for
genetic studies – used them to discover fundamental concepts such as: recombination of
homologous chromosomes, chromosomal sex determination, and the basic realization
that genes are arranged linearly on chromosomes (216).
With advances in molecular techniques, Drosophila became the first complex
multicellular organism to be used for genetic screens of genome-wide mutations affecting
biological processes in the 1970s (216). Mutations in the trp gene encoding an ion
channel gave us insight into sensory and neural processes (218–221). Mutations in the
dunce, and rutabaga genes provided insight into the role of cyclic AMP in memory and
behavioural processes (222, 223). Most of our knowledge of how genes regulate the
organization of tissues and differentiation of cells within the human embryo is gained
from analyses of their mutational effects on Drosophila embryo development (224).
Indeed, many members of the Hedgehog signalling pathway including Patched,
Smoothened, and Hedgehog itself – which plays a key role in embryonic development
across all species, and regulates tissue growth in adult vertebrates – were discovered in
Drosophila mutational screens (225).
It is currently estimated that 60 to 80 percent of genes causally linked to disease in
humans have orthologues in Drosophila (226, 227). Mutations in Drosophila patched
were found to alter the differentiation of cells in the epidermis of the embryo (217).
Consequently, gene-mapping studies identified that germ-line mutations in the human
orthologue of patched occur in Gorlin’s syndrome – which predisposes an individual to
basal-cell carcinoma – and somatic mutations in patched are apparent in most cases of
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sporadic basal-cell carcinoma (228, 229). Furthermore, the Hedgehog signalling pathway
has been implicated in mediating growth of digestive tract tumours (230, 231). In
addition to examining functional orthologues of human genes in Drosophila, many
proteins associated with a disease state in humans can be expressed in the fly to mimic
the disease phenotype, thereby providing a model for study of that disease. This approach
to modelling disease has been successfully employed to study three major
neurodegenerative diseases: Parkinson’s, Alzheimer’s, and Huntington’s (232–234).
One of the most powerful uses of Drosophila mutational genetic screens today is through
“modifier screens” (216, 235). These screens involve a phenotype caused by a known
gene of interest, and search for enhancers which worsen the severity of the phenotype, or
suppressors which lessen the phenotype. Most mutations will have no effect on the
phenotype, indicating no interplay between the mutated gene and the gene of interest
(217). In this respect they can identify gene products which play a role in the gene of
interest’s molecular pathway, while also further expanding knowledge of the function of
the gene of interest. For example, overexpression of kinase suppressor of Ras (KSR) in
eye imaginal discs causes a rough eye phenotype (REP) in the adult eye (235). A screen
of KSR-induced REP flies with flies carrying random mutations generated around
185000 mutated progeny and let to the identification 15 enhancer genes, and 4 suppressor
genes, 10 of which were known components of the Ras1 signalling pathway. This helped
to support prior biochemical evidence that KSR was a putative protein kinase functioning
downstream of RAS signalling pathways. Similar studies have been used to further our
understanding of Hairless functions in the Notch pathway, through its overexpressioninduced REP (236).
Studies utilizing Drosophila as a model organism have been paramount to our
understanding of the fundamentals of genetics and molecular biology. They have given
us insight into conserved biological processes surrounding diverse systems such as
neural, behavioural, and developmental pathways amongst many living species. In
addition they can be used as disease models, and through modifier screens, they will
continue to provide valuable insight into unresolved molecular pathways well into the
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future. The main focus of this thesis, the DNA replication-related element-binding factor
(DREF) was in fact discovered and first characterized in Drosophila (237).

1.2.1

Discovery of Drosophila DRE and DREF

Many proteins involved in DNA replication – such as DNA polymerase α and
proliferating cell nuclear antigen (PCNA), which are intimately involved in DNA
elongation – are expressed at high levels in proliferating undifferentiated cells, and
decrease when differentiation begins (238–240). In 1993, comparison of the PCNA and
DNA polymerase α 180kDa subunit promoters in Drosophila revealed a common
palindromic 8bp sequence (5’-TATCGATA) termed the DNA replication-related element
(DRE), which is required for their transcription in both transgenic flies – including
embryos and larvae – and cultured Drosophila embryonic cells (237, 241–244). Through
subsequent electrophoretic mobility shift/band shift assays (EMSA) and then cloning of
its complementary DNA (cDNA), Drosophila DREF (dDREF) was discovered and
initially characterized. dDREF is a 709 amino acid (86kDa) protein, which binds the
DRE as a homo-dimer (237, 245). Early studies revealed that mRNA expression of
dDREF was temporally similar to the expression patterns of PCNA and DNA polymerase
α, and that dDREF protein was found in the nucleus. Although only 71% identical, three
conserved regions between Drosophila virilis and D. melanogaster termed CR1 (14-182;
containing many basic residues), CR2 (432-568; containing many prolines) and CR3
(636-730; containing many acidic residues) were discovered. The locations of the
conserved regions correspond to their respective positions in the slightly longer D. virilis
742 amino acid dDREF protein. CR1 contains a boundary element-associated factor and
DREF (BED) zinc finger domain from residues 16-115 essential for homo-dimer
formation and DNA binding (237, 246).
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1.2.2

Characterization of DRE/DREF Function

Since the initial discoveries of DRE/dDREF involvement in regulating transcription from
the PCNA and DNA polymerase α promoters, DREs have been identified in the
promoters of over 150 Drosophila genes, 61 of which carry the DRE within 600bp
upstream of the transcription initiation site (247). DREF transactivation has been linked
to expression of additional proteins such as: the DNA polymerase α 73kDa subunit, E2F,
DNA primase, raf, ras2/rop, TBP, cyclin A, Orc 2, Orc 5, RFC140, SkpA, moira, osa and
dDREF itself (241–243, 248–259). Common amongst these proteins are their
involvement in DNA replication, transcriptional and cell cycle regulation, chromatin
remodelling, signal transduction for growth, and protein metabolism. Decreases in levels
of functional dDREF through dominant negative mutations or RNA interference in larvae
results in: decreased mRNA expression of dDREF-responsive genes, decreased DNA
endoreplication in endocycling salivary glands, and decreased DNA replication in mitotic
eye imaginal discs leading to an inhibition of G1-S phase progression, thereby
demonstrating its requirement for the transition of these cells through the cell cycle (260,
261). In contrast, overexpression of dDREF in cells that have begun differentiating
causes ectopic DNA replication, leading to apoptosis (256). Taken together, most
evidence points to the DRE/dDREF system as being a master regulatory system for genes
intimately involved in cellular proliferation, which gets shut off at the onset of
differentiation (247, 262). However, as is the case with many biological systems – and to
complicate matters further – there are exceptions to the rule. Knockdown of dDREF
results in irregular vein formation in wing imaginal discs through impaired EGFR
signalling, implicating dDREF in the regulation of some differentiation processes. This is
thought to be due to the dependence of the raf gene on dDREF for transactivation (263).

1.2.3

Members of the DREF Interactome

The DRE/dDREF system’s interaction network stems far beyond the genes described
above. The utilization of modifier screens described in section 1.2, as well as yeast two
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hybrid screens and co-immunoprecipitation techniques has led to the discovery of many
cellular factors which positively or negatively affect dDREF function at the genetic or
physical level.

1.2.3.1

Interactions with Positive Effects on DREF Function

In addition to the E2F gene being dDREF responsive, several dDREF responsive genes
involved in cell proliferation including: DNA polymerase α 180kDa and 73kDa, raf, and
PCNA, contain E2F as well as DRE sites. Therefore, the increase in E2F induced by
dDREF may reciprocally act to increase transcription of dDREF-responsive genes (241,
256, 264). TBP-related factor 2 (TRF2) forms complexes with dDREF and the
nucleosome remodelling factor (NURF) chromatin remodelling complex, as well as the
basal transcription machinery including transcription factors IIA and IIB. This serves to
activate transcription of genes distinct from those activated by TBP and TRF1 including
PCNA and DNA polymerase 180kDa (265–267).

1.2.3.2

Interactions with Negative Effects on DREF Function

Drosophila Mi-2 normally functions in an ATP-dependent manner to selectively
deacetylate histones at homeotic genes (268, 269). Mi-2 can also bind to the DNAbinding domain of dDREF, inhibiting dDREF from functioning (270). Reciprocally, this
binding may also inhibit Mi-2’s function as a histone deacetylase. Similarly, boundary
element associated factor of 32 kDa (BEAF-32) acts to insulate promoters from the
effects of distant regulatory elements, and prevent the spread of open and closed
chromatin states by binding to the boundary element sequence 5’-CGATA – a sequence
found within the DRE (271). dDREF and BEAF-32 antagonize each other and compete
for binding at these sites, and thus dDREF may remove BEAF-32 – or vice versa – to
shift genes into active or repressed states, modulating transcription (272). Drosophila
XNP/dATRX is a chromatin remodelling factor which contains a SWI/SNF-like
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ATPase/helicase domain, but lacks a chromatin binding domain, and therefore relies on
recruitment to chromatin through physical interactions with other proteins (273).
Recently it was found that XNP/dATRX binds dDREF at DRE sites and selectively
represses transcription of certain dDREF-responsive genes but not others – including
E2F, and osa, but not PCNA.

1.2.3.2.1

Homeodomain-Containing Proteins

Three Drosophila proteins harbouring homeodomains which all convey negative effects
on dDREF activity deserve special mention (Figure 1.6). Proteins containing
homeodomains act as transcription factors that regulate target genes in a highly regulated
temporal and spatial pattern (274). Distal-less (Dll) provides the initial signal for limb
formation (275). Zerknullt (Zen) is involved in differentiation of certain dorsal tissues in
the Drosophila embryo, including the optic lobe and amnioserosa (276). Cut expression
initiates differentiation of external sensory organs of the peripheral nervous system in
embryos, and its expression is maintained in these differentiated cells in adults (277–
280). It also determines the specificity of many cells in the central nervous system and
ovarian follicles and continues to be expressed in these tissues in adult flies (281). DII
binds directly to the DNA binding domain of dDREF, inhibiting dDREF’s transactivation
ability (275). Zen acts directly at the dDREF promoter, repressing expression of dDREF
(282). Cut recognizes and binds with high affinity to all 8bp of the DRE, antagonizing
dDREF binding in differentiated cells. It has been shown to repress expression of PCNA
and likely does so for other dDREF-responsive genes (277).
As detailed above, extensive studies in Drosophila have revealed many genes which are
regulated by the DRE/dDREF system, as well as many factors which act to positively or
negatively affect dDREF function. The necessity of dDREF for the expression of many
genes involved in DNA replication, transcriptional and cell cycle regulation, and protein
metabolism indicates that dDREF may act as a master regulator of cellular proliferation.
Furthermore, interactions of dDREF with various chromatin remodelling proteins
indicates that dDREF may regulate transcription through altering the accessibility and
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Figure 1.6 Complex interplay of proliferation and differentiation signals at dDREF
responsive genes. dDREF positively regulates several genes related to cell proliferation
including E2F, PCNA and dDREF itself. In contrast, homeodomain proteins such as Cut,
Zen, and DII which are upregulated in response to differentiation signals can negatively
regulate these genes. Zen directly suppresses dDREF expression. DII binds the DNAbinding domain of dDREF, inhibiting its function. Cut competes with dDREF for DRE
binding. BEAF32 – although not a homeodomain protein – can also compete for DRE
binding, repressing gene expression. Adapted from Matsukage et al., 2008 (262).
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Figure 1.6 Complex interplay of proliferation and differentiation signals at dDREF
responsive genes
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conformation of DNA to other transcriptional machinery. Finally, the effects of
homeodomain-containing proteins on the DRE/dDREF system provide insight on the
repression of dDREF-responsive cell proliferation genes at the onset of differentiation.

1.3

Human DREF

The Drosophila DRE/dDREF system was the first and only of its kind to be described,
until approximately 10 years ago when a mammalian counterpart was discovered in
humans. Since its discovery, only three papers have been published on the human
DRE/DREF system, with the most recent being in 2007. Notably, all three are from the
same corresponding author – Dr. Fumiko Hirose – in Japan, who discovered Drosophila
DREF in 1993.
Independently, Esposito et al. discovered the gene encoding what we now know as
hDREF in 1999, but called it Tramp (283). They localized the Tramp gene to the
pseudoautosomal region 1 (PAR1) area of the X and Y chromosomes, and revealed that
the gene encodes a protein with amino acid sequence similarity to the hAT family of
transposases, for which it was the only member discovered at the time in the human
genome. Members of the hAT family of transposases share functional and structural
characteristics with McClintock’s Activator in maize, including Drosophila hobo,
housefly Hermes, and snapdragon Tam3 (284). They discovered that Tramp contains all
the regions necessary to be an autonomous transposon – two terminal inverted repeats
(TIRs) and a transposase – and therefore they proposed that the Tramp gene originated as
an ancient transposon. However, functional analysis of the Tramp protein revealed an
inability to recognize the TIRs of its own gene, indicating that Tramp may be a nonautonomous transposon encoding a transposase which recognizes different TIRs. In this
respect it may have played a role in acquisition of transposable elements in the human
genome, excluding itself. Esposito et al. also note that the Tramp protein’s amino acid
sequence does in fact show similarity with that of Drosophila DREF, but they do not
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examine any potential biological activity of the protein as a transcription factor similar to
dDREF.

1.3.1

Discovery and Characterization of hDREF

Human DNA replication-related element-binding factor (hDREF) was originally
identified in 2003 by Ohshima et al. by utilizing a BLAST search for proteins sharing
sequence similarity with dDREF (285) (Figure 1.7). CR1 of dDREF is 27.7% identical,
with 48.1% amino acid similarity in humans. Further analysis revealed that the slightly
smaller 694 amino acid (80kDa) human DREF shares an overall 21.3% amino acid
sequence identity, and 41.0% similarity with dDREF. CR2 of dDREF shares 29.2%
identity with 46.1% similarity, and CR3 shares 21.1% identity with 51.9% similarity to
the respective corresponding regions of hDREF (285).
Two major domains exist in the hDREF protein (Figure 1.7). Both domains are conserved
amongst members of the hAT transposase family, supporting the initial discovery by
Esposito et al. that the Tramp gene encodes such a protein (283, 286). Firstly, a BED zinc
finger domain is found at the N-terminus of hDREF in the region corresponding to
dDREF CR1, and spans residues 23-72 (286). BED zinc finger domains are known DNA
binding domains found in transposases and chromatin boundary element-binding proteins
(287). Previous work in Drosophila, showed that the BED zinc finger in CR1 of dDREF
is responsible for DNA binding (245, 285). Importantly, all cysteine and histidine
residues in this domain are conserved between hDREF and dDREF, suggesting a
common DNA binding mechanism at the N-terminus through the conserved BED C2H2type zinc finger (285). However, the BED domain of hDREF on its own is not sufficient
to bind DNA, nor activate transcription in vitro (285, 286).
Second, an hATC domain is found at the C-terminus in the region corresponding to CR3
of dDREF, spanning residues 571-651 (286). hATC domains have previously been
shown to be involved in dimerization and multimerization in other hAT transposase
family members such as maize Activator and housefly Hermes (288, 289). Yamashita et
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al. found that the hATC domain in hDREF indeed facilitates and is required for homodimerization and multimerization in vitro and in vivo. A patch of hydrophobic amino
acids conserved amongst the hATC domains of several hAT transposase family members
proved to be critical for such interactions. Like its counterpart in Drosophila, hDREF is
primarily found in granular structures in the nucleus (285). hATC domain-mediated selfassociation is necessary for nuclear localization and granular pattern formation of
hDREF. Mutants that fail to self-associate do not interact with importin β1 and exhibit
cytoplasmic localization (286). In addition, residues 520-551 outside the hATC domain
contain a classical NLS-like series of basic amino acids, which are also required for
nuclear import, but not for self-association (286, 290, 291). Finally, self-association via
the hATC domain is necessary to facilitate the interaction between the BED zinc finger in
the N-terminus of hDREF and DNA. This indicates that hDREF may bind DNA as a
homo-dimer or multimer.
Expression of the hDREF protein was found to be low in serum-starved quiescent WI-38
primary cells, gradually increasing after serum addition, and reaching maximal levels
during S phase. siRNA-mediated knockdown of hDREF indicated that it might play an
essential role in the transition from G1 to S phase, as Ohshima et al. found that 0%
compared to 30% of HeLa cells stained positive for bromodeoxyuridine (BrdU) when
treated for 72 hours with hDREF-specific siRNA or scrambled siRNA respectively (285).
Further analysis in immortalized human foreskin fibroblasts revealed that cells
overexpressing hDREF proliferate faster than cells in which hDREF is knocked down
(292). In addition, hDREF was found to exist in high molecular weight complexes, which
change in a cell-cycle dependent manner. Residues 652-694 may be critical for these high
order interactions. However, the identity of other members of these complexes is
currently unknown (286).

39

Figure 1.7 Cartoon diagram of D. virilis and human DREF proteins. Regions of
hDREF that correspond to conserved regions of dDREF are shaded with the same colour.
Amino acid locations are indicated above each respective domain. Functions of each
domain and are listed beneath arrows extending from the respective regions. CR1 of
dDREF contributes to homo-dimer formation and DNA binding. The BED zinc finger of
hDREF contributes to DNA binding, and shares 27.7% identity and 48.1% similarity to
CR1 of dDREF. A functional consequence for the hDREF region corresponding to CR2
of dDREF has not been identified, so it is not depicted. The NLS of hDREF contributes
to nuclear localization, but a dDREF counterpart has not been identified. The hATC
domain of hDREF contributes to homo-dimer and multimer formation, as well as nuclear
localization. It shares 21.1% identity and 51.9% similarity to CR3 of dDREF.
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Figure 1.7 Cartoon diagram of D. virilis and human DREF proteins
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1.3.2

hDREF/hDRE Functional Analysis

Using the cyclic amplification and selection of targets (CASTing) method, a palindromic
10bp consensus recognition sequence (5’-TGTCG(C/T)GA(C/T)A) for hDREF was
identified, and termed the hDRE. Five bases of this sequence (5’-CGATA) directly
overlap with those in the dDRE and the Drosophila BEAF-32 insulator recognition site
(271, 285). Mutational analysis of the hDRE revealed that the central six bases (5’TCG(C/T)GA) are the most important for hDREF binding. Over 500 hDRE-like
sequences matching at least 7 of 10 bases of the hDRE exist in the human genome, and
many of these are found within promoter regions for genes encoding proteins involved in
cell proliferation. This finding indicates that hDREF may be functionally conserved from
Drosophila to humans. Table 1.2 lists several candidate hDREF target genes, which
contain hDRE-like sequences in their promoter regions, and classifies them based on
their involvement in: DNA replication and metabolism, cell cycle regulation,
transcription, or protein synthesis.
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Table 1.2 Select human genes containing hDRE-like sequences
Category

Gene

hDRE Base Pair
Matches (/10)
10
DNA Replication and
Histone H1
Deoxycytidine
Kinase
9
Metabolism
Deoxyguanosine Kinase
8
Thymidine Kinase
7
Topoisomerase IIa
7
DNA Polymerase δ
7
DNA Polymerase γ
7
p14ARF
9&8
Cell Cycle Regulation
p21WAF1
8&7
CDC25C
8
CDC25A
7
CDK6
8
Cyclin D3
7
Cyclin T1
7&7
RNA polymerase II large subunit
9&8
Transcription
RNA polymerase III 48-kDa subunit
7
NF-κB
9&7
TAFII55
8&7
Surf-5
8
Protein Synthesis
Asparagine Synthetase
8&7
rRNA
7
EF1A-2
7
8&8
RPS6
9
RPL10A
9
RPL12
Note: Genes with blue letters were selected in previous studies to examine whether their
transcription is affected by hDREF (285, 292). Genes with two numbers listed contain
two hDRE-like sequences.
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1.3.2.1

hDREF and Histone H1 Gene Expression

Histone H1 is responsible for the higher order structure of DNA, binding the core
nucleosomes and linker DNA between them, and compacting the chromatin into a 30nm
fibre from a simple “beads-on-a-string” form (293, 294). Its expression is tightly
regulated by the cell cycle and intricately tied to DNA replication (295). It is expressed at
low levels in serum-starved and differentiated cells, and transiently increases during the
G1 to S phase transition (295–297). This expression pattern mimics that of hDREF.
Intriguingly, the histone H1 promoter (FNC16/H1.5) contains an hDRE matching all 10
bases of the consensus sequence. hDREF was found to specifically bind the H1 promoter
at this site in vitro. Transient luciferase assays in HeLa cells using a luciferase reporter
plasmid driven by the histone H1 promoter co-transfected with hemagglutinin (HA)tagged hDREF revealed that hDREF may possibly activate transcription at the H1
promoter (285). In support of this, Ohshima et al. showed that an 88% knockdown of
hDREF protein resulted in a 74% reduction in histone H1 mRNA levels in asynchronous
HeLa cells using semi-quantitative real time polymerase chain reaction (RT-PCR).
However, the reduction in histone H1 mRNA levels resulting from hDREF knockdown
could be indirect and due to other factors, such as inhibited progression into S phase.

1.3.2.2

hDREF and Ribosomal Protein Gene Expression

Ribosomes are responsible for protein synthesis in all organisms, and are composed of
two subunits containing rRNA and 79 ribosomal proteins (RPs), all of which are essential
for ribosomal function (292, 298, 299). Much like hDREF and histone H1, rRNA and RP
levels are tightly linked to progression through the cell cycle, with transcription initiating
and increasing during G1 phase, reaching maximal expression in S and G2 phases (300–
302). Ribosome biogenesis has even been implicated as a proliferative checkpoint in the
cell (302). The basic theory behind this concept is as follows: In mitogen stimulated cells,
ribosome biogenesis is upregulated via the preferential loading of RP mRNAs onto preexisting ribosomes. This generates more ribosomes, increasing the translational capacity
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of the cell, thereby allowing the translation of mRNAs less preferred by the ribosomes,
such as those for the cyclin cell cycle regulators (302). The process of ribosome
biogenesis in fact consumes 80% of the energy of a proliferating cell. Thus, a cell-cycle
checkpoint exists until enough ribosomes have accumulated, which will not occur unless
the cell has grown enough and accumulated enough nutrients to support division. In
support of this, less than 50% knockdown of a single RP – RPS6 – has been shown to
impair cellular proliferation (292).
Interestingly, 37 of 79 RP genes contain an hDRE-like sequence matching at least eight
bases of the hDRE consensus sequence, 22 of which contain it within 200-bp upstream of
the transcription start site (TSS) (292). Furthermore, the hDRE in 20 of these genes is
centered around 60bp upstream of the TSS. Thus Yamashita et al. decided to examine
whether hDREF regulates expression of three select ribosomal proteins, as a means of
further discovering the role of hDREF in regulating cell proliferation. RPS6 contains two
hDRE-like sequences, at 51 and 538 bases upstream of the TSS, each matching eight of
ten consensus bases. Ribosomal proteins Large 10A (RPL10A) and Large 12 (RPL12)
contain one at 41 and 56 bases upstream of the TSS respectively, matching nine of ten
consensus bases (Table 1.2). hDREF was found to bind the hDRE-like sequence of RPS6
in vitro via EMSA, and the promoters – albeit weakly – of all three selected RP genes in
vivo via chromatin immunoprecipitation (ChIP). Transient luciferase assays in HeLa cells
using a luciferase reporter plasmid driven by the RPS6, RPL10A, or RPL12 promoter cotransfected with HA-tagged hDREF revealed that hDREF may weakly activate
transcription of these genes. Deletion of the hDRE abrogated transcriptional activation,
indicating that the increases in luciferase activity observed from co-transfected HAhDREF were due to the hDREF-hDRE interaction. Additionally, Yamashita et al. showed
that a 65% knockdown of hDREF reduced mRNA levels of all three genes, and resulted
in an overall reduction in protein synthesis by 25%.
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1.4

Rationale, Hypothesis, and Objectives

Dr. Peter Pelka – a former post-doctoral fellow in our lab – initially identified an
interaction between E1A and hDREF through mass spectrometry analysis of
immunoprecipitates of E1A in vitro. Although a multitude of potential E1A targets were
identified, I decided to pursue hDREF for two main reasons. Firstly, it is a transcription
factor involved in the expression of several genes related to cell proliferation, and its
expression increases during S-phase. The two main functions of E1A are to modulate
cellular and viral transcription, and to induce a G1-to-S phase transition, and therefore the
binding and manipulation of hDREF could be important for both of these functions.
Secondly, because hDREF is poorly characterized, studies with the well characterized
E1A protein could serve to better elucidate hDREF function. Based on this rationale, we
hypothesize that the interaction between E1A and hDREF contributes to adenovirus
induced transcriptional modulation and viral replication in HAdV-5 infected host cells.
To test the hypothesis, four main objectives were set:
1) Confirm the interaction of E1A with hDREF and map the binding site on E1A
2) Examine the effects of hDREF on transcription in vitro
3) Determine the effects of hDREF on specific viral and cellular gene transcription
in vivo
4) Observe how changes in hDREF expression affect viral replication
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2

Materials and Methods

2.1

Cells Cultures

HT1080 human fibrosarcoma cells, HeLa cervical cancer cells, Human Embryonic
Kidney (HEK) 293 cells, and IMR-90 primary human lung fibroblast cells were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM; Multicell) supplemented with 10%
fetal bovine serum

(Gibco), 100U penicillin mL-1(Multicell), and 100μg mL-1

streptomycin (Multicell). Cells were grown in a 37oC incubator with 5% CO2.

2.2

Plasmids

Plasmids 1-24, 26, 27, and 30-32 were constructed and utilized by previous members in
our lab (Table 2.1). Gal4 DNA-binding domain (Gal4-DBD) fusion plasmids express
proteins with N-terminal Gal4-DBD tags (215, 303). GFP fusion plasmids express
proteins with N-terminal GFP tags (78, 304). Plasmid 28 (pGL3-H1p) was constructed as
previously described, however the histone H1 promoter sequence was inserted into a
promoter-less and enhancer-less pGL3-basic backbone vector (Promega), instead of one
containing the SV40 promoter (285). This precluded the need to subsequently remove the
SV40 promoter. Plasmid 29 (pcDNA3-HA-hDREF) was obtained by generous donation
from Dr. Fumiko Hirose at the University of Hyogo, Japan, and was described previously
(285). Plasmid 25 (Gal4-DBD-hDREF) was created by restriction digesting full length
hDREF out of plasmid 29 with SalI and HindIII (New England Biolabs) and inserting it
into the same restriction sites of the parent vector pM. This generated an N-terminal
Gal4-DBD-tagged hDREF. All plasmids were maintained in Escherichia coli strain
DH5α. Large-scale preparations of plasmid DNA were generated using the HiPure
Plasmid Midiprep kit (Invitrogen) according to the manufacturer’s guidelines.
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Table 2.1. List of Plasmids
#

Name

Parent
Vector

Characteristics

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

GFP-13S Ad12
GFP-13S Ad3
GFP-13S Ad5
GFP-13S Ad9
GFP-13S Ad4
GFP-13S Ad40
GFP-12S
GFP-11S
GFP-10S
GFP-9S
GFP-1-82
GFP-CR2
GFP-CR3
GFP-Exon2
GFP-Δ1-82
GFP-1-29
GFP-30-69
GFP-70-82
GFP-1-82 (Δ1-14)
GFP-1-82 (Δ4-25)
GFP-1-82 (Δ26-35)
pGFP
Gal4-DBD-1-82
Gal4-DBD-CR3
Gal4-DBD-hDREF
pM
pGL2-(UAS)6-Luc

pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
pGFP
N/A
pM
pM
pM
N/A
pGL2-Basic

28

pGL3-H1p-Luc

pGL3-Basic

29
30

pcDNA3-HA-hDREF
pcDNA3-HA

pcDNA3-HA
N/A

31
32

pcDNA3-pRb
pcDNA3

pcDNA3
N/A

Full length 13S E1A of Ad12
Full length 13S E1A of Ad3
Full length 13S E1A of Ad5
Full length 13S E1A of Ad9
Full length 13S E1A of Ad4
Full length 13S E1A of Ad40
12S E1A of Ad5
11S E1A of Ad5
10S E1A of Ad5
9S E1A of Ad5
AA 1-82 of Ad5 E1A
AA 93-139 of Ad5 E1A
AA 139-204 of Ad5 E1A
AA 187-289 of Ad5 E1A
AA 93-289 of Ad5 E1A
AA 1-29 of Ad5 E1A
AA 30-69 of Ad5 E1A
AA 70-82 of Ad5 E1A
Plasmid #11 but Δ1-14
Plasmid #11 but Δ4-25
Plasmid #11 but Δ26-35
Expresses GFP only; Control
AA 1-82 of Ad5 E1A
AA 139-204 of Ad5 E1A
Full length hDREF
Expresses Gal4-DBD only; Control
Luciferase reporter plasmid;
Contains 6 UASs and a minimal
promoter controlling luciferase gene
expression
Luciferase reporter plasmid;
Contains full length histone
H1promoter (-571bp to -1bp)
controlling luciferase gene
expression
Full length hDREF
Expresses hemagglutinin only;
Control and fill-in DNA
Full length pRb
Non-coding plasmid; Fill-in DNA

Note: Gal4-DBD = AA1-147 of Gal4; UAS (Upstream Activation Sequence) = The
Gal4-DBD binding site
Table 2.1 List of plasmids
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2.3

Plasmid Transfections

10cm2 dishes (Sarstedt) were used for all transfections in co-immunoprecipitation
experiments, and 1x106 HT1080 or HeLa cells were plated 24 hours before transfection.
6-well plates (Sarstedt) were used for transfections in luciferase assay experiments, and
2x105 HT1080 and HeLa cells were plated 24 hours before transfection. Purified plasmid
DNA was transfected into cells using X-tremeGENE HP DNA Transfection Reagent
(Roche) as per the manufacturer’s protocol.

2.4

Viruses and Infections

All HAdV infections were carried out at a multiplicity of infection (MOI) of 5 PFU per
cell. The inoculated cells were incubated at 37oC with 5% CO2 until their collection at
time points indicated by individual experiments. All HAdVs used were derived from the
HAdV-5 dl309 (wild-type; WT) background which contains a small deletion in the E3
region, knocking out the E3 14.7K, 14.5K and 10.4K proteins (163, 305). Viruses utilized
throughout the experiments, and their respective E1A mutations are as follows: dl312
(ΔE1A), dl343 (Non-functional E1A due to frameshift after the codon for amino acid 20),
dl309 (WT), dl1101 (Δ4-25), dl1102 (Δ26-35), dl1103 (Δ30-49). Besides dl312 which
expresses no E1A, all viruses express both 13S and 12S E1A.

2.5

2.5.1

Co-immunoprecipitation and Western Blotting

Co-immunoprecipitation of HT-1080 and HeLa Cell Lysates

HT-1080 cells co-transfected with indicated plasmids, and HAdV-infected HeLa cells
were collected at 24 and 12 hours post-transfection or post-infection respectively. Cells
were washed in 1mL of Phosphate-Buffered Saline (PBS; Multicell), pelleted, and lysed
in 1mL of 0.5% NP-40 lysis buffer (0.5% NP-40, 150mM NaCl, 50mM Tris-HCl pH 7.8)
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containing 0.5% Complete Protease Inhibitor Cocktail (Sigma-Aldrich). Cells were
centrifuged at 13000g to pellet the cell debris, and then 1mL of lysate was transferred to
cold 1.5mL Eppendorf tubes. 20μl of lysate was transferred to new tubes to be used as a
2% input loading and plasmid expression control. The remaining 980μl of lysate was
subject to immunoprecipitation. 1μL of α-Green Fluorescent Protein (GFP) rabbit
polyclonal antibody (Ab) or 80μL of the hybridoma-produced M73 α-E1A Ab (Table
2.2), along with 125μL of a 10% slurry of protein-A sepharose beads (Sigma-Aldrich)
suspended in E1A Buffer (50mM Hepes pH7, 0.1% NP-40, 250mM NaCl) was added to
each experimental tube. Samples were incubated with gentle rocking at 4oC for two to
four hours. Immunoprecipitated lysates were spun down at 13000g and washed five times
in NP-40 lysis buffer to diminish non-specific background binding. Protein-antibodybead complexes were suspended in 25μL of 2X LDS Sample Buffer (Invitrogen)
containing 0.1M dithiothreitol (DTT). Input lysates were suspended in 10μL of 3X LDS
Sample Buffer. All samples were then boiled for five minutes at 100oC to denature
proteins and separate them from the antibody-bead complexes. Proteins were separated
on NuPAGE 4-12% Bis-Tris polyacrylamide gradient gels (Invitrogen) and then
transferred onto a polyvinylidene fluoride membrane (PVDF; Amersham) according to
the supplier’s protocol. Membranes were blocked in Tris-Buffered Saline containing
0.1% Tween-20 (Sigma-Aldrich) (TBS-T), and 5% weight/volume skim milk powder
(BioShop), for one hour at room temperature. The membrane was then incubated in
20mL of the indicated diluted primary antibody (Table 2.2) overnight at 4oC. After
washing in TBS-T four times for eight minutes each, the membrane was incubated in
20mL of the indicated diluted horseradish peroxidase (HRP)-conjugated species-specific
secondary antibody (Table 2.2) for 45 minutes at room temperature. The membrane was
subject to four final TBS-T washes for eight minutes each, before detecting protein bands
using the Luminata Forte Western HRP substrate (Millipore) according to the supplier’s
recommendations. Images were developed on high performance Hyperfilm ECL film
(Amersham) using an SRX-101A automated developer (Konika Minolta Medical
Imaging).
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Table 2.2 List of antibodies
Specificity

Actin
GFP
GFP
HA
Gal4-DBD
hDREF
E1A (M73)
E1A (M73)
Rat IgG
Rabbit IgG

Description

Usage

Rabbit
polyclonal
Rabbit
polyclonal
Rabbit
polyclonal
Rat
monoclonal
Mouse
monoclonal
Rabbit
polyclonal
Mouse
monoclonal
Mouse
monoclonal
Goat

Primary

Dilution
Factor
from Stock
1:2000

Company

Catalogue #

SigmaAldrich
Clontech

M-7023

Primary

1:2000

IP

Clontech

632592

Primary

1:1000
(1µL)
1:2000

Roche

11867423001

Primary

1:2000

Santa Cruz

Sc-510

Primary

1:1000

Abcam

Ab48355

Primary

Secondary

1:100000

In house
hybridoma
In house
hybridoma
Thermo
Scientific
Santa Cruz

N/A

Secondary

1:200
(100µL)
1:12.5
(80µL)
1:200000

Goat

IP

632592

N/A
31470
Sc-2004

Rabbit
Secondary
1:200000
Santa Cruz
Sc-358923
Mouse IgG
Note: Primary and secondary antibodies are diluted and applied to membranes in TBS-T
containing 5% skim milk powder. Immunoprecipitation (IP) antibodies are added directly
to 1mL of lysate
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2.5.2

Western Blotting of Other HT-1080, HeLa, and IMR-90 Cell
Lysates

All Western blots were performed in identical fashion subsequent to loading the proteins
on a gel. There were slight changes in protocol prior to this step, however, for Western
blots that were not the product of co-immunoprecipitation experiments. First, the volume
of NP-40 lysis buffer varied among experiments. Cells plated on: 10cm2 dishes were
lysed in 1mL of NP-40 buffer; 6-well dishes were lysed in 200μL; and 12-well dishes
were lysted in 100μL. IMR-90 cells plated on 6-well dishes were lysed in 50μL of NP-40
lysis buffer. Next, the protein concentration of each lysate was measured using a
Bradford DC Protein assay kit (Bio-Rad), such that 20-30 μg of total protein from each
sample could accurately be loaded on a gel.

2.6

2.6.1

Luciferase Assays

Gal4 Luciferase Assays

Cells were transfected with 0.1μg or 1.0μg of the pGL2-(UAS)6-Luc reporter (Plasmid
27) and indicated Gal4-DBD fusion plasmids (Table 2.1). A total of 2μg of plasmid DNA
was transfected into each sample, using empty pcDNA3 plasmid as fill-in to maintain
identical total DNA concentrations among all transfections. After 24 hours in HT-1080
cells, or 48 hours in HeLa cells, cells were lysed in 200μL of Reporter Lysis Buffer
(Promega E397A) diluted in PBS. To detect luciferase production, 50μL of Luciferase
Substrate (Promega E151A) was mixed with 50μL of lysate immediately prior to
detection of light by a Lumat LB 9507 luminometer (Berthold). Lysates were also subject
to Bradford assays and Western blots as described in section 2.5.2. Results were initially
normalized based on protein concentration as determined by Bradford assays, and then
related to luciferase activity readout of a Gal4-DBD empty plasmid control.
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2.6.2

Histone H1 Promoter Luciferase Assays

Histone H1 promoter luciferase assays were carried out as described in section 2.7.1,
however 0.1μg of pGL3-H1p-Luc (Plasmid 28) was used as a reporter (Table 2.1). The
pcDNA3-HA-hDREF plasmid was co-transfected in increasing concentrations. pcDNA3HA empty vector was used as fill-in DNA to reach a total of 2μg of transfected plasmid
DNA. Results were normalized initially based on protein concentration, and then related
to luciferase activity readout of samples transfected with only the pGL3-H1p plasmid.

2.7

siRNA Knockdown

Downregulation of hDREF was performed using two combined Silencer Select siRNAs
(s17567/s17568; Ambion). siRNA transfections were carried out using Silentfect (BioRad), with slight modifications to the manufacturer’s protocol. In HeLa cells used for
quantitative RT-PCR experiments, siRNAs were transfected 18 hours after plating 1x106
cells on a 10cm2 dish, to a final concentration of 15nM (7.5nM of each hDREF siRNA).
15μL of Silentfect was used per well. In IMR-90 cells used for viral plaque assay
experiments, siRNAs were transfected 18 hours after plating 1x105 cells on 6-well dishes,
to a final concentration of 10nM (5nM of each hDREF siRNA). 2μL of Silentfect was
used per well. Scrambled siRNA (Negative Control No. 2; AM4613; Ambion) was used
as a control.

2.8

Quantitative RT-PCR

HeLa cells were subject to siRNA knockdown of hDREF as indicated in section 2.7. 24
hours later, the cells were subcultured to 12-well dishes, at 1x105 cells per well. After a
total of 72 hours post-siRNA knockdown, cells were infected with the indicated viruses at
an MOI of 5 PFU per cell. At 6 and 10 HPI, total RNA was prepared from HeLa cells
using Trizol reagent (Ambion). 1μg of RNA was reverse transcribed to cDNA using the
qScript cDNA SuperMix kit (Quanta) as per the manufacturer’s instructions. cDNA was
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quantified according to the manufacturer’s protocol, using PerfeCTa SYBR Green
FastMix (Quanta) and oligonucleotide primers that recognize the indicated target gene
(Table 2.3). Quantification was performed by the MyiQ Single Color Real-Time PCR
Detection System (Bio-Rad). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as an internal control. Results were analyzed using the 2-(ΔΔCT) method, normalizing
values first to GAPDH and then to mock infected samples.

2.9

Viral Plaque Assays

IMR-90 cells were transfected with hDREF siRNA as indicated in section 2.7. Cells were
then grown to confluence, and then contact inhibited cultures were incubated for an
additional 3 days, to allow for complete growth arrest (77, 78). Next, cells were infected
with the indicated viruses at an MOI of 5 PFU per cell. IMR-90 cells and supernatant
were collected at 4, 48, and 120 HPI. Samples were subjected to three cycles of freezethawing between -80oC and 4oC, in order to lyse the cells and release the virus. HEK293
cells were then plated on 48-well dishes and grown to confluence. Next, 100µL of the
indicated serially diluted virus previously collected from the IMR-90 cells was used to
inoculate them. Cells were briefly incubated for 1 hour at 37oC and 5% CO2.
Subsequently, the inoculum was removed, and 300μL of SeaPlaque Low Melting Point
Agarose (Lonza) mixed in a ratio of 1.5:1 with 2X DMEM (Gibco) was applied as an
overlay. 8 days later plaques were enumerated and used to determine viral titre.
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Table 2.3 List of oligonucleotide primers used for Real-Time PCR
Gene

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

GAPDH
E2e
E3
E4
H1
RPS6

ACTGCTTAGCACCCCTGGCCAA
GGGGGTGGTTTCGCGCTGCTCC
GAGGCAGAGCAACTGCGCC
GCCCCCATAGGAGGTATAAC
TTTCTTGCCACCATGTCGGA
ACGCTCTGGGTGAAGAATGG

ATGGCATGGACTGTGGTCATGAGTC
GCGGATGAGGCGGCGTATCGAG
GCTCTCCCTGGGCGGTAAGCCGG
GGCTGCCGCTGTGGAAGCGC
TTGCCTTCTTCTTAGCCGGG
AAGACACCCTGCTTCATGGG

Amplicon
Size (bp)
79
138
151
129
85
88

Note: All primers were supplied by Sigma-Aldrich. Annealing stage of RT-PCR was
consistently performed at 55oC.
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Results

3

3.1
Mapping the Interaction Between E1A and hDREF
to Specific Regions of the E1A Protein

3.1.1

Identification of Conserved Interactions between hDREF and
13S E1A of Representative Members of HAdV Species A
Through F

Many important interactions with cellular factors such as CtBP, GCN5, pRb, and p300
are conserved amongst various serotypes from the six main species of HAdV (166, 189,
304). Therefore, the identification of new factors displaying conserved interactions with
E1A amongst different species possibly indicates an important role for those factors
during the HAdV life cycle. The interaction between HAdV-5 13S E1A and hDREF was
initially identified in our lab by Dr. Peter Pelka, through mass spectrometry analyses of
immunoprecipitates of E1A (Data not shown). To examine whether the interaction with
hDREF was conserved across species A through F, we utilized co-immunoprecipitation
techniques. HT-1080 cells were co-transfected with plasmids encoding HA-tagged
hDREF, and GFP-tagged 13S E1A from representative members of HAdV species A
through F: HAdV-12, 3, 5, 9, 4, and 40 respectively. 24 hours later, cells were collected,
lysed, and subject to immunoprecipitation using an α-GFP antibody. Western blots were
subsequently carried out to determine which serotypes co-immunoprecipitated hDREF
through E1A. Results indicated that there is indeed a conserved interaction between
hDREF and 13S E1A from serotypes 12, 3, 5, 9, and 4 of species A through E, but not
serotype 40 of species F (Figure 3.1). Since HAdV-5 is well characterized, and the
majority of molecular tools in our lab were constructed from HAdV-5, it was the serotype
of choice for subsequent experiments in this thesis (65).
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Figure 3.1 The interaction of hDREF with 13S E1A from various HAdV species.
HT-1080 cells were co-transfected with 1μg of a plasmid encoding HA-tagged hDREF,
and 7μg of a plasmid encoding GFP-tagged 13S E1A from representative members of
HAdV species A through F: HAdV-12, 3, 5, 9, 4, and 40 respectively. Empty GFP vector
was used as a negative control. 24 hours later, cells were collected, lysed, and subject to
immunoprecipitation using an α-GFP antibody. Western blots were then carried out using
α-HA, and α-GFP antibodies.
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Figure 3.1 The interaction of hDREF with 13S E1A from various HAdV species
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3.1.2

Interaction of hDREF with E1A Isoforms

As depicted in Figure 1.4, each E1A protein contains regions shared with 13S, but also
contains specifically spliced regions. Binding of proteins to certain E1A isoforms, but not
others can be used to expedite the process of mapping an interaction. For instance,
binding to 13S but not 12S would indicate potential binding in CR3. Thus, we next
examined whether any of the other four isoforms of E1A from HAdV-5 were able to bind
hDREF. HT-1080 cells were co-transfected with plasmids encoding HA-tagged hDREF,
and GFP-tagged 13S, 12S, 11S, 10S, and 9S E1A from HAdV-5. 24 hours later, cells
were collected, lysed, and subject to immunoprecipitation using an α-GFP antibody.
Western blots were subsequently carried out to determine which isoforms hDREF coimmunoprecipitated with. Results indicated that all five isoforms of HAdV-5 E1A can
bind hDREF in vitro (Figure 3.2). Since the only residues common to all five isoforms
are the first 26 amino acids, our initial results suggested that hDREF binds to E1A
through the N-terminus (77).

3.1.3

Identification of the hDREF Binding Site on E1A

In order to more precisely define the location of the hDREF binding site on E1A, we
performed a series of co-immunoprecipitation experiments, using increasingly specific
E1A mutants. HT-1080 cells were co-transfected with plasmids encoding HA-tagged
hDREF, and GFP-tagged E1A constructs. 24 hours later, cells were collected, lysed, and
subject to immunoprecipitation using an α-GFP antibody. Western blots were
subsequently carried out to determine which E1A mutants hDREF could coimmunoprecipitate with.

Initially we examined deletion mutants containing conserved regions of E1A. The
following plasmids were transfected, encoding various portions of 13S E1A: AA1-82
which contains the N-terminus and also CR1 spanning residues 42-72; AA93-139 which

59

Figure 3.2 The interaction of hDREF with different HAdV-5 isoforms. HT-1080 cells
were co-transfected with 1μg of a plasmid encoding HA-tagged hDREF, and 7μg of a
plasmid encoding GFP-tagged 13S, 12S, 11S, 10S, or 9S E1A from HAdV-5. Empty
GFP vector was used as a negative control. 24 hours later, cells were collected, lysed, and
subject to immunoprecipitation using an α-GFP antibody. Western blots were then
carried out using α-HA, and α-GFP antibodies.
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Figure 3.2 The interaction of hDREF with different HAdV-5 isoforms
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contains CR2 spanning residues 116-139; AA139-204 which contains CR3 spanning
residues 144-191; AA187-289 which contains CR4 spans residues 240-288; or AA93-289
which contains the entire protein besides the N-terminus and CR1 (166). Consistent with
Figure 3.2, my results indicated that hDREF binds E1A within the first 82 amino acids
(Figure 3.3). In addition, hDREF does not bind regions outside the first 82 amino acids,
as indicated by the lack of binding to the construct expressing GFP-tagged residues 93289. It is important to note that the exact figure displayed was chosen as the clearest
representation of multiple replicates of this experiment. The band representing coimmunoprecipitated hDREF through residues 1-82 was consistently as intense as that for
13S E1A, throughout all replicates. Despite the fact that a faint band indicating coimmunoprecipitated hDREF was present for residues 144-191, and even weaker bands
were present for binding of residues 93-139 and 93-289, I believe they represent false,
non-specific interactions. In other replicates of this experiment these hDREF bands never
appeared more intense than those depicted in Figure 3.3, were frequently absent from the
blots, and occasionally appeared less intense than the negative control, despite the fact
that their respective GFP-tagged E1A constructs were consistently expressed at higher
levels than GFP-13S and GFP-1-82.

Next, we transfected plasmids encoding three small, non-overlapping fragments of the
first 82 amino acids of E1A. Residues 1-29 displayed hDREF binding, while residues
30-69 and 70-82 were deficient for binding (Figure 3.4). Finally, we transfected plasmids
encoding amino acids 1-82 with the following deletions: Δ1-14; Δ4-25; Δ26-35. A
deletion of residues 1-14 did not appear to affect binding of the N-terminus to hDREF, as
a band nearly as intense as full length 1-82 was detected (Figure 3.5). In contrast,
deletions of residues 4-25 or 26-35 severely reduced hDREF co-immunoprecipitation.
Low intensity hDREF bands were visible in all replicates of the experiment, indicating
weak binding of hDREF to these N-terminal deletion mutants. Collectively the results
obtained from figures 3.2 through 3.5 indicate that residues 15-26 of E1A are sufficient
for a level of hDREF binding comparable to that of the N-terminal 82 amino acids, and
thus full length 13S.
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Figure 3.3 The N-terminal 82 amino acids of E1A bind to hDREF. HT-1080 cells
were co-transfected with 1μg of a plasmid encoding HA-tagged hDREF, and 7μg of a
plasmid encoding a GFP-tagged fragment of E1A: amino acids 1-82, 93-139, 139-204,
187-289, or 93-289. Empty GFP vector was used as a negative control. GFP-tagged 13S
E1A was used as a positive control. 24 hours later, cells were collected, lysed, and
subject to immunoprecipitation using an α-GFP antibody. Western blots were then
carried out using α-HA, and α-GFP antibodies.
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Figure 3.3 The N-terminal 82 amino acids of E1A bind to hDREF
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Figure 3.4 The N-terminal 29 amino acids of E1A independently bind to hDREF.
HT-1080 cells were co-transfected with 1μg of a plasmid encoding HA-tagged hDREF,
and 7μg of a plasmid encoding a small GFP-tagged fragment of the first 82 amino acids
of E1A: 1-29, 30-69, or 70-82. Empty GFP vector was used as a negative control. GFPtagged 1-82 of E1A was used as a positive control. 24 hours later, cells were collected,
lysed, and subject to immunoprecipitation using an α-GFP antibody. Western blots were
then carried out using α-HA, and α-GFP antibodies.
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Figure 3.4 The N-terminal 29 amino acids of E1A independently bind to hDREF
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Figure 3.5 Deletion of residues 4-25 or 26-35 reduce the ability of the N-terminal 82
amino acids of E1A to bind hDREF. HT-1080 cells were co-transfected with 1μg of a
plasmid encoding HA-tagged hDREF, and 7μg of a plasmid encoding GFP-tagged amino
acids 1-82 of E1A with deletions in residues 1-14, 4-25, or 26-35. Empty GFP vector was
used as a negative control. GFP-tagged 1-82 of E1A was used as a positive control. 24
hours later, cells were collected, lysed, and subject to immunoprecipitation using an αGFP antibody. Western blots were then carried out using α-HA, and α-GFP antibodies.
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Figure 3.5 Deletion of residues 4-25 or 26-35 reduce the ability of the N-terminal 82
amino acids of E1A to bind hDREF
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3.1.4

Confirmation of the Interaction between E1A and hDREF
during Infection

Although our previous results identified an interaction between E1A and hDREF, they
were derived from transfection based assays using overexpressed proteins. To determine
whether the interaction between E1A and endogenous hDREF could occur during an
actual infection, I decided to use a more relevant model. HeLa cells were infected at an
MOI of 5 PFU per cell with HAdV-5 virus expressing wild-type E1A (dl309), E1A
mutated in various N-terminal regions (dl1101/Δ4-25; dl1102/Δ26-35; or dl1103/Δ3049), or not expressing E1A (dl312). 12 hours later, cells were collected, lysed, and
subject to immunoprecipitation using the M73 αE1A antibody. Western blots for E1A
and endogenous hDREF were subsequently performed. My results indicated that 13S
E1A produced during an HAdV-5 infection can interact with endogenous hDREF (Figure
3.6). Results were also consistent with those in Figure 3.5, confirming a greater reduction
in the ability of E1A to bind endogenous hDREF when residues 4-25 and 26-35 are
deleted, as compared to when residues 30-49 are deleted.

In summary, the results of our co-immunoprecipitation transfection-based and infectionbased experiments indicate a definite interaction between E1A and hDREF. The
interaction is conserved amongst representative serotypes from HAdV species A through
E but not F, and all 5 isoforms of HAdV-5 E1A can bind hDREF. The N-terminal 29
amino acids appear to form a primary binding site for hDREF, of which residues 15-26
are sufficient for binding. The goal of our mapping experiments was to identify a
minimal binding region in E1A which was necessary for the hDREF interaction. We then
intended to alter that region to create an HAdV-5 derivative encoding an E1A mutant
unable to bind hDREF. The virus would have been used to study the effects of the
hDREF-E1A interaction on viral and cellular gene transcription, as well as viral
replication (objectives three and four). However, due to time restraints for the completion
of a Master’s degree, this was not feasible. Since both the Δ4-25 and Δ26-35 E1A
mutants displayed reduced binding – but neither completely abolished binding – a series
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Figure 3.6 Deletions in residues 4-25 and 26-35 reduce the ability of 13S E1A
produced during infection to bind endogenous hDREF. HeLa cells were infected at an
MOI of 5 PFU per cell with HAdV-5 mutants possessing distinct E1A phenotypes: dl312
(ΔE1A), dl309 (WT), dl1101 (Δ4-25), dl1102 (Δ26-35), or dl1103 (Δ30-49). 12 hours
later, cells were collected, lysed, and subject to immunoprecipitation using the M73 αE1A antibody. Western blots for E1A and endogenous hDREF were subsequently
performed.
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Figure 3.6 Deletions in residues 4-25 and 26-35 reduce the ability of 13S E1A
produced during infection to bind endogenous hDREF
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of more refined deletion mutants within these regions would have to be constructed and
tested. In lieu of the time restraints, we proceeded to address the second objective of this
thesis, and subsequently utilize siRNA against hDREF to specifically address objectives
three and four.

3.2
Determining the Effects of hDREF on Transcription
in vitro

3.2.1

Selecting an Appropriate Cell Line

Previously published luciferase experiments indicated that hDREF was a weak transactivator in HeLa cells (285, 292). For these experiments, the full length promoters for
genes encoding histone H1, RPS6, RPL10A, and RPL12 were cloned into promoter-less
and enhancer-less luciferase reporter plasmids. All of the respective promoters contained
an hDRE-like sequence, matching 8 to 10 bases of the hDRE consensus. Their results
indicated that upon transfection of 100ng of the reporter and 100 to 300ng of a plasmid
encoding HA-hDREF, luciferase activity ranged from 1.2 to approximately 2.8 fold
higher then when HA-hDREF was not transfected. The authors stated that further
investigation of hDREF as a trans-activator was warranted. I decided to repeat one of the
previous experiments which examined the histone H1 promoter-containing luciferase
reporter. In addition, we performed a series of luciferase assays, in order to examine the
trans-activation ability of hDREF through various methods. To select an appropriate cell
line, we performed a Western blot on lysates from several asynchronously growing
human cell lines (Figure 3.7). Results indicated that out of the four cell lines examined,
HeLa cervical carcinoma cells expressed the highest amount of endogenous hDREF,
while IMR-90 primary human lung fibroblast cells expressed the least. HT1080
fibrosarcoma cells and transformed HEK293 cells expressed intermediate levels of
hDREF. We hypothesized that examining hDREF trans-activation at the histone H1
hDRE-containing promoter using transfection based luciferase assays would yield more
significant results in HT1080 cells than HeLa cells. The increased levels of endogenous
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Figure 3.7 Comparison of endogenous hDREF levels in asynchronous populations of
four cell lines. Asynchronous IMR90, 293, HT1080, and HeLa cells were collected, and
lysed. Western blots were performed using α-hDREF and α-actin antibodies.
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Figure 3.7 Comparison of endogenous hDREF levels in asynchronous populations
of four cell lines
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hDREF in HeLa cells may promote high background activation at hDRE-containing
promoters. This could act to obscure any observable differences which would otherwise
be obtained from transfecting small amounts of HA-hDREF expression plasmid. Thus we
chose to use the easily transfectable HT1080 cell line for all luciferase assays. In
addition, all experiments were later repeated separately in HeLa cells, although fewer
conditions were tested in each experiment.

3.2.2

Examining hDREF Transactivation of a Simple Gal4 DNABinding Domain-Responsive Luciferase Reporter

We initially examined whether hDREF had the ability to act as a trans-activator by
recruiting the transcriptional machinery to a minimal promoter. HT1080 cells were cotransfected with increasing amounts of a plasmid encoding Gal4 DNA-binding domaintagged hDREF (Gal4-DBD-hDREF) and 0.1μg of a Gal4-responsive luciferase reporter
plasmid (pGL2-(UAS)6-Luc). The reporter plasmid contains the luciferase gene under the
control of a minimal promoter, with six upstream activation sequences (UASs) acting as
Gal4 binding sites. A construct encoding Gal4-DBD-tagged amino acids 1-82 of E1A
(Gal4-DBD-1-82) was used as a positive control, as the N-terminus of E1A is known to
act as a strong trans-activator (166). A construct encoding the Gal4-DBD alone was used
as a negative control, since the Gal4-DBD requires an activation domain to trans-activate
through the UAS. 24 hours after transfection, cells were collected, lysed, and luciferase
activity was measured. Results were initially normalized based on protein concentration
as determined by Bradford assays, and then calculated relative to the luciferase activity
value of the negative control. When 1.6ng, 8.0ng, 1.0μg, 1.5μg, or 1.9μg of the Gal4DBD-hDREF plasmid were transfected, significant decreases in luciferase activity
relative to the negative control were observed (*=p<0.05; **=p<0.01; ***=p<0.001)
(Figure 3.8). A similar lack of activation was observed in HeLa cells; however, no
significant reductions in luciferase activity relative to the negative control were observed
in these cells (Figure 3.9). In both cell lines, the Gal4-DBD-1-82 fusion activated
strongly. Western blots also demonstrated that the Gal4-DBD-hDREF fusion expression
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Figure 3.8 Transactivation of a Gal4-DBD-responsive luciferase reporter plasmid
containing a minimal promoter by Gal4-DBD-hDREF (HT1080). HT1080 cells were
co-transfected with 1.6ng to 1.9μg of a plasmid encoding Gal4 DNA-binding domaintagged hDREF (Gal4-DBD-hDREF) and 0.1μg of a Gal4-responsive luciferase reporter
plasmid (pGL2-(UAS)6-Luc). Empty pcDNA3 plasmid was transfected to maintain a
total of 2μg of transfected plasmid DNA in all samples. 1.9μg of a construct encoding
Gal4-DBD-tagged amino acids 1-82 of E1A (Gal4-DBD-1-82) was transfected as a
positive control. 1.9μg of a construct encoding Gal4-DBD alone was used as a negative
control. 24 hours after transfection, cells were collected, lysed, and luciferase activity was
measured. A) Results were initially normalized based on protein concentration as
determined by Bradford assays, and then calculated relative to the luciferase activity
present in the negative control. Results are indicative of the means (±SEM) of at least
three independent experiments (* = p<0.05; ** = p<0.01; *** = p<0.001). B) Western
blots were performed using α-Gal4 and α-actin antibodies to examine expression of Gal4hDREF under each transfection condition.
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Figure 3.8 Transactivation of a Gal4-DBD-responsive luciferase reporter
plasmid containing a minimal promoter by Gal4-DBD-hDREF (HT1080)
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Figure 3.9 Transactivation of a Gal4-DBD-responsive luciferase reporter plasmid
containing a minimal promoter by Gal4-DBD-hDREF (HeLa). HeLa cells were cotransfected with 0.1 to 1.9μg of a plasmid encoding Gal4 DNA-binding domain-tagged
hDREF (Gal4-DBD-hDREF) and 0.1μg of a Gal4-responsive luciferase reporter plasmid
(pGL2-(UAS)6-Luc). Empty pcDNA3 plasmid was transfected to maintain a total of 2μg
of transfected plasmid DNA in all samples. 1.9μg of a construct encoding Gal4-DBDtagged amino acids 1-82 of E1A (Gal4-DBD-1-82) was transfected as a positive control.
1.9μg of a construct encoding Gal4-DBD alone was used as a negative control. 48 hours
after transfection, cells were collected, lysed, and luciferase activity was measured. A)
Results were initially normalized based on protein concentration as determined by
Bradford assays, and then related to luciferase activity readout of the negative control.
Results are indicative of the means (±SEM) of at least three independent experiments (*
= p<0.05). B) Western blots were performed using α-Gal4 and α-actin antibodies to
examine expression of Gal4-hDREF under each transfection condition.
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Figure 3.9 Transactivation of a Gal4-DBD-responsive luciferase
reporter plasmid containing a minimal promoter by Gal4-DBDhDREF (HeLa)
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increased in parallel with increased levels of transfected expression vector (Figures 3.8 B
and 3.9 B). My results show that hDREF on its own does not have the ability to
independently recruit the transcriptional machinery to a minimal promoter and drive
luciferase gene expression.

3.2.3

Effect of hDREF on E1A-Induced Transactivation of a
Simple Gal4 DNA-Binding Domain-Responsive Luciferase
Reporter

Although hDREF did not appear to function as an independent activator of transcription
in the experiments described above, it remained possible that its interaction with E1A
could modulate E1A's ability to activate transcription. To test this, I next examined
whether hDREF specifically enhanced or repressed the ability of Gal4-DBD-tagged E1A
trans-activation domains to induce transcription from the pGL2-(UAS)6-Luc reporter. My
previous data indicated that amino acids 1-82 of E1A could bind hDREF strongly, but
that CR3 could not bind hDREF strongly (Figure 3.3). Thus we hypothesized that hDREF
would enhance Gal4-DBD-tagged transcriptional activation by E1A AA1-82 but not by
E1A CR3. HT1080 cells were co-transfected with 0.1μg of the pGL2-(UAS)6-Luc
reporter plasmid, and 0.9μg of plasmids encoding either Gal4-DBD-1-82, Gal4-DBDCR3, or Gal4-DBD alone, along with increasing amounts of pcDNA3-HA-hDREF
plasmid. A plasmid encoding pRb was used as a co-transfected negative control with
Gal4-DBD-1-82, as pRb interacts with the N-terminus of E1A and is a transcriptional
repressor (306, 307). 24 hours after transfection, cells were collected, lysed, and
luciferase activity was measured. Results were initially normalized based on protein
concentration as determined by Bradford assays, and then calculated relative to the
luciferase activity value of the Gal4-DBD control. Transfection of 1.0μg of pcDNA3HA-hDREF resulted in significant 3.5 fold (p=0.0421) and 8.2 fold (p=0.0225)
reductions of AA1-82 and CR3-induced luciferase activity respectively (Figure 3.10).
When lower amounts of hDREF plasmid were transfected, reductions in AA1-82-induced
luciferase activity were not observed; however, non-significant concentration-dependent
decreases to CR3-induced luciferase activity were consistently observed. In addition,
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transfection of 1.0μg of pcDNA3-HA-hDREF plasmid significantly reduced the
background luciferase activity induced by the Gal4-DBD alone by 1.9 fold (p=0.0041).
Similar trends were observed in HeLa cells, however no significant changes in
transcriptional activation were detected (Figure 3.11). My results indicate that hDREF
non-specifically reduces the ability of AA1-82 and CR3 of E1A to activate transcription
of a minimal promoter in a concentration-dependent manner.

3.2.4

Evaluating hDREF Transactivation of a Luciferase Gene
Under Control of the hDRE-Containing Histone H1 Promoter

My previous results indicated that hDREF does not have the ability to trans-activate a
minimal promoter (Figure 3.8/3.9), and that transfection based overexpression of hDREF
resulted in a reduction of trans-activation by AA1-82 and CR3 of E1A at a minimal
promoter, which occurred irrespective of their individual ability to bind hDREF (Figure
3.10/3.11). It is important to note, however, that the minimal promoter in the pGL2(UAS)6-Luc reporter contains only a TATA box. To complete our assessment of the
effects of hDREF on transcription in vitro, we chose to replicate the original experiment
published by Ohshima et al., which examined hDREF transactivation through the full
length histone H1 promoter (285). Since the histone H1 promoter contains an hDRE site
which matches all ten bases of the consensus sequence, it could potentially provide a
more accurate depiction of the role of hDREF in trans-activation than the artificial
context of a minimal promoter.

I cloned the histone H1 promoter (-537bp to -1bp) from HeLa cells, into a promoter-less
and enhancer-less luciferase reporter plasmid to create pGL3-H1p-Luc as previously
described in section 2.2. HT1080 cells were then transfected with 0.1μg of the pGL3H1p-Luc reporter, and increasing amounts of pcDNA3-HA-hDREF. 24 hours after
transfection, cells were collected, lysed, and luciferase activity was measured. Results
were initially normalized based on protein concentration as determined by Bradford
assays, and then calculated relative to the luciferase activity value of the sample
containing the reporter plasmid alone. Consistent with previously published data, my
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Figure 3.10 Effects of hDREF on the ability of Gal4-DBD-tagged amino acids 1-82
and CR3 of E1A to transactivate a Gal4-DBD-responsive luciferase reporter
plasmid (HT1080). HT1080 cells were co-transfected with 0.1μg of a Gal4-responsive
luciferase reporter plasmid (pGL2-(UAS)6-Luc) and either: 1.0ug Gal4-DBD plasmid
alone, 1.0ug Gal4-DBD-1-82 plasmid, or 1.0ug Gal4-DBD-CR3 plasmid along with 01.0ug of pcDNA3-HA-hDREF. Empty pcDNA3-HA plasmid was transfected to maintain
a total of 2μg of transfected plasmid DNA in all samples. 1.0μg of a plasmid encoding
pRb was used as a co-transfected negative control with Gal4-DBD-1-82. 24 hours after
transfection, cells were collected, lysed, and luciferase activity was measured. Results
were initially normalized based on protein concentration as determined by Bradford
assays, and then related to luciferase activity readout of the Gal4-DBD negative control.
Results are indicative of the means (±SEM) of at least three independent experiments (*
= p<0.05; ** = p<0.01).
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Figure 3.10 Effects of hDREF on the ability of Gal4-DBD-tagged amino acids 1-82
and CR3 of E1A to transactivate a Gal4-DBD-responsive luciferase reporter
plasmid (HT1080)
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Figure 3.11 Effects of hDREF on the ability of Gal4-DBD-tagged amino acids 1-82
and CR3 of E1A to transactivate a Gal4-DBD-responsive luciferase reporter
plasmid (HeLa). HeLa cells were co-transfected with 0.1μg of a Gal4-responsive
luciferase reporter plasmid (pGL2-(UAS)6-Luc) and either: 1.0ug Gal4-DBD plasmid
alone, 1.0ug Gal4-DBD-1-82 plasmid, or 1.0ug Gal4-DBD-CR3 plasmid along with 01.0ug of pcDNA3-HA-hDREF. Empty pcDNA3-HA plasmid was transfected to maintain
a total of 2μg of transfected plasmid DNA in all samples. 1.0μg of a plasmid encoding
pRb was used as a co-transfected negative control with Gal4-DBD-1-82. 48 hours after
transfection, cells were collected, lysed, and luciferase activity was measured. Results
were initially normalized based on protein concentration as determined by Bradford
assays, and then related to luciferase activity readout of the Gal4-DBD negative control.
Results are indicative of the means (±SEM) of at least three independent experiments.
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Figure 3.11 Effects of hDREF on the ability of Gal4-DBD-tagged amino acids 1-82
and CR3 of E1A to transactivate a Gal4-DBD-responsive luciferase reporter
plasmid (HeLa)
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results indicated that hDREF can act as a weak trans-activator at the histone H1
promoter, significantly increasing luciferase activity by 1.21 fold (p=0.0362), and 1.11
fold (p=0.005) over basal levels when 0.2 and 0.3μg of pcDNA3-HA-hDREF plasmid
were transfected respectively (Figure 3.12A). However, the previous experiments never
examined the effects of transfecting more than 0.3μg of the pcDNA3-HA-hDREF
plasmid. My results indicate a significant 1.4 fold (p=0.0208) and 4 fold (p<0.0001)
decrease in luciferase activity compared to basal levels when 1.0 and 1.9μg of pcDNA3HA-hDREF plasmid were transfected respectively. A similar trend was observed in HeLa
cells (Figure 3.13). A 1.15 fold increase, and a significant 3.3 fold decrease (p=0.0012) in
luciferase activity compared to basal levels were observed when 0.3μg and 1.9μg of
pcDNA3-HA-hDREF plasmid were transfected into HeLa cells respectively. Next, I tried
increasing the transfected amount of pGL3-H1p-Luc reporter plasmid by 10 fold in
HT1080 cells, to assess whether concentration of the reporter was the limiting factor in
luciferase production and activity (Figure 3.12C). However, my results indicated a
similar trend, whereby increasing the amount of transfected pcDNA3-HA-hDREF
significantly reduced luciferase activity.

In summary, my in vitro luciferase assay results suggest that hDREF does not possess the
ability to independently trans-activate at a basic minimal promoter, but does weakly
trans-activate at the hDRE-containing histone H1 promoter when small amounts of
pcDNA3-HA-hDREF plasmid are transfected into cells. At high concentrations of
transfected pcDNA3-HA-hDREF plasmid, two observable events occur. Firstly, a drastic
reduction in trans-activation at the histone H1 promoter is detected. Second, the abilities
of E1A AA1-82 and CR3 to trans-activate through a minimal promoter are significantly
reduced. Although the results of these luciferase assays served to provide initial insight
into the effects of hDREF on transcription, it is important to note that luciferase assays by
nature can be highly artificial. This is due to the fact that they are transfection-based
experiments, and thus rely heavily on the overexpression of proteins which could prove
toxic to cells.
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Figure 3.12 Effect of hDREF on transactivation of a luciferase reporter plasmid
under the control of the histone H1 promoter (HT1080). HT1080 cells were cotransfected with either 0.1μg (A) or 1.0μg (C) of the pGL3-H1p-Luc reporter plasmid and
0-1.9μg of pcDNA3-HA-hDREF. Empty pcDNA3-HA plasmid was transfected to
maintain a total of 2μg of transfected plasmid DNA in all samples. 24 hours after
transfection, cells were collected, lysed, and luciferase activity was measured. Results
were initially normalized based on protein concentration as determined by Bradford
assays, and then related to luciferase activity readout of the pGL3-H1p-Luc reporter
alone. Results are indicative of the means (±SEM) of at least three independent
experiments (* = p<0.05; ** = p<0.01; *** = p<0.001). B) Western blots were performed
using α-HA, α-hDREF and α-actin antibodies to examine protein expression.
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Figure 3.12 Effect of hDREF on transactivation of a luciferase reporter plasmid
under the control of the histone H1 promoter (HT1080)
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Figure 3.13 Effect of hDREF on transactivation of a luciferase reporter plasmid
under the control of the histone H1 promoter (HeLa). HeLa cells were co-transfected
with either 0.1μg of the pGL3-H1p-Luc reporter plasmid and 0-1.9μg of pcDNA3-HAhDREF. Empty pcDNA3-HA plasmid was transfected to maintain a total of 2μg of
transfected plasmid DNA in all samples. 48 hours after transfection, cells were collected,
lysed, and luciferase activity was measured. A) Results were initially normalized based
on protein concentration as determined by Bradford assays, and then related to luciferase
activity readout of the pGL3-H1p-Luc reporter alone. Results are indicative of the means
(±SEM) of at least three independent experiments (** = p<0.01). B) Western blots were
performed using α-HA, α-hDREF and α-actin antibodies to examine protein expression.
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Figure 3.13 Effect of hDREF on transactivation of a luciferase reporter plasmid
under the control of the histone H1 promoter (HeLa)
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3.3
The Effects of hDREF on Viral and Cellular Gene
Transcription During an HAdV-5 Infection
To better understand the effects of hDREF on viral and cellular gene transcription in a
dynamic system, I decided to utilize an HAdV-5 infection model. HeLa cells were
transfected with a combination of hDREF specific siRNAs or scramble siRNA and
incubated for 72 hours. On average, a 40% knockdown of hDREF was achieved. We then
infected the cells at an MOI of 5 PFU per cell, with HAdV-5 mutants expressing either
wild-type E1A (dl309) or E1A that is non-functional due to a frameshift after the codon
for amino acid 20 (dl343). At 6 and 10 HPI, total RNA was extracted using Trizol
reagent. RNA was reversed transcribed to cDNA, and specific transcripts were quantified
using RT-PCR. Results were analyzed using the 2-(ΔΔCT) method, normalizing values first
to GAPDH and then to dl343-infected samples (Figure 3.14). No significant differences
in activation of the E2 early gene were detected between the hDREF knockdown and
scramble siRNA-treated samples. However, knockdown of hDREF resulted in decreased
activation of the E3 early gene at both time points, with a significant 6 fold decrease
(p=0.0282) at 10 HPI. Interestingly, hDREF knockdown resulted in significant decreases
in activation of the E4 early gene at both time points. A significant 4.4 fold decrease
(p=0.0497) in E4 activation was observed at 6 HPI, and a significant 7.8 fold decrease
(p=0.0099) was detected at 10 HPI. No significant differences were observed between the
hDREF knockdown and scramble siRNA-treated samples for activation of the cellular
histone H1 and RPS6 genes, which contain promoters with hDRE-like sequences.
Interestingly however, my results seem to indicate that E1A affects transcription of both
of these cellular genes at 6 HPI, as activation of these genes was from 1.4 to 2.3 fold
higher than in dl343 infected cells, regardless of the hDREF phenotype.

The results of my quantitative RT-PCR experiments carried out in a HeLa cell infection
model indicate that hDREF plays a significant role in activation of the HAdV-5 early
genes E3 and E4. However, 40% knockdown of hDREF does not affect activation of viral
E2 early, or cellular histone H1 and RPS6 genes during infection.
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Figure 3.14 Effects of hDREF on early viral gene and cellular gene transcription
during an HAdV-5 infection. HeLa cells were transfected with a combination of
hDREF specific siRNAs or scramble siRNA and incubated for 72 hours, yielding 40%
knockdown on average. Subsequently cells were infected at an MOI of 5 PFU per cell,
with HAdV-5 mutants expressing either wild-type E1A (dl309) or E1A that is nonfunctional due to a frameshift after the codon for amino acid 20 (dl343). Total RNA was
extracted at 6 and 10 HPI, and 1μg was reverse transcribed to cDNA. HAdV-5 E2, E3,
and E4 as well as cellular histone H1 and RPS6 transcripts were quantified by RT-PCR.
Results were analyzed using the 2-(ΔΔCT) method, normalizing values first to GAPDH and
then to dl343-infected samples. Results are indicative of the means (±SEM) of at least
three independent experiments (* = p<0.05; ** = p<0.01) and are expressed as fold
activation of specific genes in dl309-infected samples relative to dl343-infected samples.

92

Figure 3.14 Effects of hDREF on early viral gene and cellular gene transcription
during an HAdV-5 infection
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3.4

The Effect of hDREF on Viral Replication

Since hDREF significantly affected viral early gene transcription, I decided to examine
whether hDREF played a role in overall viral replication. We chose to use IMR-90
primary human lung fibroblasts for studies of viral replication, as they can be easily
growth arrested and have been used in previous viral replication studies (77, 78). IMR-90
cells were transfected with a combination of hDREF specific siRNAs or scramble
siRNA, and were contact inhibited for 3 days after reaching confluence. The growth
arrested cells were then infected at an MOI of 5 PFU per cell with HAdV-5 mutants
expressing either wild-type E1A (dl309) or no E1A (dl312). Viruses were collected at 4,
48, and 120 HPI, and serial dilutions of the virus were applied to monolayers of HEK293
cells to assess viral titre via plaque assay. Only data for 120 HPI are shown, as no
significant differences in viral titre were observed between dl309 viral samples collected
at 4 or 48 HPI (Figure 3.15 A). In addition, the viral titre of dl312 remained at
approximately 1.15x105 PFU per mL at 4, 48 (Data not shown) and 120 HPI, regardless
of hDREF expression (Figure 3.15 B). This indicated that the dl312 virus did not
replicate in growth arrested cells as expected, due to a lack of E1A. A significant 1.8 fold
decrease (p=0.0176) in dl309 viral titre at 120 HPI was detected when samples were
treated with hDREF siRNA versus scramble siRNA (Figure 3.15 A), coinciding with an
approximate 100% knockdown of hDREF (Figure 3.15 B). Therefore, these results
indicate that knockdown of hDREF reduces the overall yield of virus and likely plays a
significant role in HAdV-5 replication.
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Figure 3.15 Effects of hDREF on HAdV-5 replication. IMR-90 cells were transfected
with a combination of hDREF specific siRNAs or scramble siRNA, and then growth to
confluence. Cells were incubated for 3 days after reaching confluence, to arrest their
growth due to contact inhibition. Subsequently cells were infected at an MOI of 5 PFU
per cell, with HAdV-5 mutants expressing either wild-type E1A (dl309) or no E1A
(dl312). Viruses were collected at 4, 48 and120 HPI, and serial dilutions of the virus were
applied to monolayers of HEK293 cells to assess viral titre via plaque assay. A) Results
for viral samples collected at 120 HPI are shown, and are indicative of the mean viral
titres (±SEM) of at least three independent experiments (* = p<0.05). B) Western blots
were performed using α-hDREF, α-E1A, and α-actin antibodies. Approximately 100%
knockdown of hDREF was observed in each sample, at every time points.
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Figure 3.15 Effects of hDREF on HAdV-5 replication
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4

Discussion

4.1

Mapping the Interaction Between E1A and hDREF

Utilization of co-immunoprecipitation techniques revealed that there is an interaction
between 13S E1A and hDREF, and that this interaction is conserved amongst
representative serotypes of HAdV species A through E – HAdV 12, 3, 5, 9, and 4
respectively – but not HAdV-40 of species F. My results also indicate that all five
isoforms of HAdV-5 E1A – 13S, 12S, 11S, 10S, and 9S – can bind hDREF. Finally, I
discovered that the N-terminal 29 amino acids of E1A form a primary binding site for
hDREF and that residues 15-26 appear sufficient for binding. Indeed all of my results
support this conclusion, as only the first 26 amino acids are common amongst all
isoforms of E1A, and a deletion of residues 1-14 does not affect hDREF binding. The
final goal of my mapping experiments was to identify specific amino acids in E1A which
are necessary for the hDREF interaction, and mutate those residues to create an HAdV-5
derivative encoding an E1A mutant unable to bind hDREF. This virus would allow for
careful study of the effects of the E1A-hDREF interaction on viral and cellular events.
Unfortunately, due to time constraints, I was unable to identify which specific individual
residues of the identified region are necessary for binding hDREF.

A future direction of this project will likely involve the identification of essential residues
for hDREF binding. To aid in this process I generated a sequence alignment of residues
15-26 from 13S E1A of HAdV-12, 3, 5, 9, 4, and 40 using Clustal-W (Figure 4.1).
Amino acids 19 and 24 are highly conserved in all serotypes, and therefore would be
candidate residues to test for deficiencies in binding using point mutations. Interestingly,
residues 20 and 21 are highly conserved in species A through E but not F. Since HAdV40 of species F does not bind hDREF, these residues – which change an aliphatic amino
acid to an aromatic one, and an acidic residue to an uncharged residue – may prove to
strongly contribute to hDREF binding. The leucine and isoleucine residues at positions
19, 20, 23, and 24 in HAdV-5 E1A have previously been shown to be essential for
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interactions with various cellular factors including p300, CBP, TBP, pCAF, and GCN5,
as mutation of any one of these residues to alanine severely reduces binding to each
protein (308). If any of these four residues is discovered to be essential for hDREF
binding, creating a virus encoding E1A that is specifically deficient in hDREF binding
for use in functional studies may prove problematic. Co-disruption of the interactions
with hDREF as well as other trans-activators like TBP and p300 would preclude the
ability to isolate the specific consequences of the E1A-hDREF interaction. It may be
possible to instead map the interaction to specific regions of hDREF, as the two major
functional and structural domains of the protein have been mapped and therefore
mutations in these areas can be avoided (286). The inherent problem with this is that
because hDREF is still poorly characterized, deletions in certain areas of the protein
could alter its normal function without any possible way of knowing that this had
occurred. This would also make it difficult to determine the exact effects of the E1AhDREF interaction.

To conclusively test whether residues 15-26 are necessary for the hDREF interaction, a
full length 13S E1A with residues 15-26 deleted would have to be constructed and tested.
However, although residues 15-26 are sufficient for binding, they may not all be required
and additional residues outside this region may contribute to binding. Amino acid 26 of
E1A is not highly conserved amongst representative members of HAdV species A
through F (Figure 4.1). Thus, it is unlikely that deletion of only residue 26 in this binding
site would cause such a drastic decrease in hDREF binding, or that deletion of residues
15-25 would still allow for hDREF binding if this were the correct scenario (Figures 3.5
and 3.6). A more probable interpretation of the data is that several residues both within,
and external to the 15-26 region act in a cooperative fashion to bind hDREF. This would
serve to explain why deletion of residues 15-25 or 26-35 reduces hDREF binding, but
does not completely inhibit it. Indeed residues 16-28 are predicted to form an
amphipathic α-helix in HAdV-5 (78). Therefore it is possible that deletions or mutations
of individual or small groups of residues within this structure act to reduce, but not
completely eliminate hDREF binding. Perhaps a deletion of residues 16-28 entirely or
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Figure 4.1 Alignment of E1A residues 15-26. Amino acids 15 to 26 of E1A from
representative serotypes of HAdV species A through F were aligned using Clustal-W.
Darker shaded boxes indicate more conserved residues. Amino acids 20 and 21 of
HAdV-40 E1A are highlighted in red to indicate extreme dissimilarity from the highly
conserved residues present in the E1A proteins of HAdV-12, 3, 5, 9, and 4.
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Figure 4.1 Alignment of E1A residues 15-26
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mutations of key residues to disrupt the amphipathic characteristics of the helix would
completely abolish hDREF binding.

Although I have shown an interaction with hDREF and E1A, it is important to note that it
has not yet been determined as to whether this interaction is direct or indirect. Since
hDREF is a transcriptional regulator and the N-terminus of E1A has been shown to
interact with an extensive number of transcriptional regulators, it is entirely possible that
E1A indirectly binds hDREF through other factors (214, 308). Indeed, hDREF has been
shown to be involved in high molecular weight multiprotein complexes, although the
identities of other members of these complexes are unknown (286). To test whether the
interaction is indirect or direct, co-immunoprecipitation experiments using purified
recombinant E1A and hDREF could be performed. Finally – direct or not – an intriguing
future direction of this project would be to identify factors which co-immunoprecipitate
in complexes with hDREF and observe whether the identities of factors in these
complexes are altered in the presence of E1A. This would not be surprising as E1A alters
the abilities of pRb, CtBP, and hBre1 to interact with their normal cellular targets (175,
199, 214). Such studies could provide advanced insight into the normal function of
hDREF, as well as the purpose of the hDREF manipulation by E1A.

4.2
Analysis of the Effects of hDREF on Transcription
using Luciferase Assays
Based on transient luciferase assays in both HT1080 and HeLa cells, it appears that
hDREF does not possess the capability to trans-activate at a minimal promoter containing
only a TATA box. In addition, when large amounts of pcDNA3-HA-hDREF plasmid are
co-transfected with plasmids encoding Gal4-DBD-tagged AA1-82 or CR3 of E1A, the
abilities of these known trans-activators to drive luciferase expression through a minimal
promoter are significantly reduced. Consistent with previously published results, hDREF
can weakly trans-activate at the hDRE-containing histone H1 promoter when small
amounts of pcDNA3-HA-hDREF plasmid are transfected into cells (285). However, at
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higher amounts of transfected pcDNA3-HA-hDREF, significant reductions in transactivation at this promoter were detected.

4.2.1

Gal4-DBD-hDREF Trans-activation of the pGL2-(UAS)6-Luc
Reporter

My observation that Gal4-DBD-hDREF cannot drive expression of the pGL2-(UAS)6Luc reporter is very surprising, as it indicates that hDREF lacks the ability to bind and
recruit the general transcription factors (GTFs) and RNA polymerase II to the TATA box.
Although approximately 76% of human genes lack a TATA box within their core
promoter regions, the recruitments of TBP and the rest of the transcription factor II D
(TFIID) complex, as well as the other GTFs, are still required to drive expression of these
genes (309, 310). Previously published results indicate that hDREF trans-activates –
albeit weakly – several genes containing hDRE sequences in their promoter (285, 292).
Therefore it seems unlikely that hDREF would be unable to bind at least one general
transcription factor to enhance transcription at hDRE-containing genes. Two potential
mechanisms may serve to explain the observed results. First, the action of hDREF
binding to DNA may serve to induce a conformational change in hDREF, revealing a
binding site for TBP or other GTFs. Indeed, conformational changes have been observed
in the PhoB transcription factor upon DNA binding, although whether this affects its
function or not is unknown (311). In this respect, the Gal4-DBD-hDREF fusion protein
would not be able to trans-activate the pGL2-(UAS)6-Luc reporter, because although it
contains Gal4 binding sites, this reporter does not contain an hDRE. To address this
hypothesis, a modified luciferase reporter could be constructed, which inserts single, or
multiple hDRE sites in tandem upstream of the minimal promoter instead of the existing
Gal UASs. One would then expect that trans-activation of the luciferase gene would
increase as more hDRE elements were added.

A second explanation is that the fusion of a Gal4-DBD domain to the N-terminus of
hDREF inherently prevents activation of the reporter plasmid via steric hindrance. This
explanation revolves around the discovery that self-association of hDREF via the C-
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terminal hATC domain is necessary for multiple functions of hDREF including DNA
binding (286). The fusion of a Gal4-DBD domain to the N-terminus of hDREF could
prevent hDREF from properly dimerizing. If dimerization is required for hDREF to
interact with the GTFs, this would completely abolish trans-activation. The opposite
scenario is also a logical explanation. Since the Gal4-DBD must dimerize to bind DNA,
self-association of hDREF could preclude Gal4-DBD dimerization due to steric
hindrance, or due to dimerization between Gal4-DBD-hDREF and endogenous hDREF.
This would prevent targeting of the Gal4-DBD-hDREF protein to the UAS, resulting in a
lack of luciferase expression. In addition, the overexpressed, undirected Gal4-DBDhDREF protein would be free to bind and sequester putatively targeted GTFs, thereby
reducing trans-activation of the pGL2-(UAS)6-Luc reporter below basal levels, as
observed in Figure 3.8.

4.2.2

Alteration of Gal4-DBD-1-82 and Gal4-DBD-CR3 Transactivation of the pGL2-(UAS)6-Luc Reporter

Contrary to our hypothesis that the addition of hDREF would enhance Gal4-DBD-tagged
transcriptional activation by E1A AA1-82, but not by E1A CR3, it actually appeared to
reduce trans-activation by both (Figures 3.11 and 3.12). Importantly, trans-activation by
the negative control Gal4 vector was also reduced when the same amount (1μg) of
pcDNA3-HA-hDREF plasmid was added. This indicates that the apparent repression of
transcription occurred in a non-specific fashion. Causation could be similar to what may
have been occurring in experiments examining Gal4-DBD-hDREF trans-activation of the
same pGL2-(UAS)6-Luc reporter. It is possible, but unlikely, that the small eight amino
acid HA-tag interferes with hDREF dimerization; however, the answer may be that
hDREF must bind DNA through the hDRE to induce a self-conformational change,
allowing for subsequent GTF binding. This scenario would preclude the ability to
identify any interaction specific effects between E1A AA1-82 and hDREF on transactivation of the luciferase gene, due to a lack of an hDRE in the pGL2-(UAS)6-Luc
reporter. If this explanation is correct, addressing the original hypothesis that hDREF
enhances E1A AA1-82 trans-activation but not CR3 trans-activation, would prove
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difficult. Since the Gal4-DBD-tagged E1A constructs and HA-hDREF would each target
the UAS and hDRE sequences independently in a modified pGL2-(UAS)6-Luc reporter
containing an hDRE, it would be impossible to distinguish whether differences in E1Ainduced trans-activation were due to an interaction with hDREF or not. To circumvent
this issue, it could be possible to instead examine whether the addition of untagged E1A
AA1-82 or CR3 could enhance trans-activation of an hDRE-containing luciferase
reporter plasmid. In fact, this is a future direction of the project. Since I already
constructed the pGL3-H1p-Luc reporter plasmid, and confirmed previous reports that
hDREF can trans-activate at the histone H1 hDRE-containing promoter (285), this
experiment could be easily carried out. By co-transfecting reporter, and increasing
amounts of untagged AA1-82 or CR3 of E1A, one could observe how the interaction of
hDREF with the N-terminus of E1A affects hDREF-induced trans-activation of the H1
promoter.

A second explanation for the non-specific reduction in E1A AA1-82 and CR3-induced
trans-activation upon addition of large amounts of pcDNA3-HA-hDREF plasmid is more
likely. Perhaps – due to overexpression – the HA-hDREF protein saturates the cellular
transcription machinery, binding and sequestering a single, or multiple, rate limiting
GTFs, such that they are no longer available for trans-activation of the minimal promoter.
This would best explain why addition of 1μg of pcDNA3-HA-hDREF plasmid reduces
the background activation of luciferase by the Gal4-DBD protein alone, which should not
bind hDREF, and on its own does not trans-activate. If this rationale is correct, a
combination of several overexpression-related mechanisms may cumulatively contribute
to explain why enhanced trans-activation is not apparent when hDREF is co-transfected
with Gal4-DBD-AA-1-82 of E1A. As previously mentioned, the first explanation is
sequestration of rate limiting GTFs by hDREF. The second explanation is that unbound
hDREF protein may compete for E1A binding with hDREF protein that is bound to
GTFs. Finally, since hDRE elements are not present in the pGL2-(UAS)6-Luc reporter
plasmid but are present on the chromosomes found in human HT1080 and HeLa cells, it
is entirely possible that hDREF is directing transcriptional complexes containing E1A
AA1-82 to these promoters, instead of the Gal4-DBD directing the complexes to the
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pGL2-(UAS)6-Luc reporter. The latter two mechanisms would serve to explain the
reduction in apparent trans-activation by Gal4-DBD-AA1-82, but not Gal4-DBD-CR3 or
Gal4-DBD alone. The first mechanism would explain reductions in all samples.

In retrospect, two extra controls would have helped to elucidate what is happening to the
pGL2-(UAS)6-Luc reporter system upon addition of large amounts of pcDNA3-HAhDREF plasmid. The pRb tumour suppressor has previously been shown to interact with
CR1 and CR2 of E1A, but not CR3 (166). As expected, when I co-transfected 1μg of a
plasmid encoding pRb with one encoding Gal4-DBD-1-82, a reduction in trans-activation
was observed (Figures 3.10 and 3.11). Co-transfection of the pRb plasmid with the Gal4DBD-CR3 plasmid would have strengthened the argument that the results observed upon
addition of hDREF were occurring in a non-specific fashion. pRb would be expected to
have no effect on CR3-induced trans-activation, unless it too was sequestering rate
limiting transcriptional machinery in a concentration dependent manner, thereby
indicating an inherent problem with utilizing such high amounts of transfected plasmid
DNA. Secondly, Western blots of lysates used in these experiments would have helped to
understand the effects of hDREF concentration on E1A-induced trans-activation. Finally,
it is entirely possible that my choice of using 0.1, 0.5 and 1.0μg of transfected pcDNA3HA-hDREF completely excluded the appropriate expression level of HA-hDREF which
avoids sequestration effects and yields enhanced transactivation by Gal4-DBD-1-82. If
this experiment were to be repeated in the future, testing more concentrations of
transfected pcDNA3-HA-hDREF DNA, particularly within the range of 0.1 to 0.5μg
would be a logical next step.

4.2.3

HA-hDREF Trans-activation of the pGL3-H1p-Luc Reporter

Consistent with previously published results, I’ve shown that hDREF can weakly, but
significantly trans-activate at the hDRE-containing histone H1 promoter when small
amounts of pcDNA3-HA-hDREF plasmid are transfected into HT1080 cells (285).
Similar trends were observed in HeLa cells as well, however the results across multiple
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replicates were less consistent, and significant levels of trans-activation were not
observed in these cells. However, my own data indicate that when higher amounts of
pcDNA3-HA-hDREF are transfected, significant reductions in trans-activation of the
pGL3-H1p-Luc reporter occur in both cell lines. Several explanations may rationalize the
observed results, which appear to indicate a biphasic trans-activation response to hDREF.
Firstly, hDREF may be negatively auto-regulating itself after it passes a certain threshold
of protein expression, thereby reducing hDREF-induced trans-activation at the histone
H1 promoter. Auto-regulation of transcription factors is a common mechanism across all
eukaryotes and assists in the control of expression of many cell cycle specific
transcription factors (312). Negative auto-regulation provides a mechanism to quickly
reach steady-state expression levels of individual transcription factors, without having to
immediate degrade those proteins when they reach excess cellular amounts (312, 313).
Although it is currently unknown whether or not the hDREF gene promoter on human
chromosomes contains an hDRE element, five dDRE elements are found within the
dDREF promoter in Drosophila, and dDREF auto-regulates itself through one of the
dDRE elements located 211 to 218 bases upstream of the TSS (259). Indeed the
expression pattern of total hDREF within HT1080 cells in my experiments resembles that
of negative auto-regulation. Transfection of greater than 0.3μg of pcDNA3-HA-hDREF
results in levels of hDREF that start to decline (Figure 3.12B). At first glance this seems
like a probable answer, but similar effects are not observed in HeLa cells. Results in
HeLa cells reveal a similar trend in luciferase activity, but not in hDREF expression
(Figure 3.12 and 3.13). Although auto-regulation of transcription factors can be a celltype specific control mechanism, the discrepancies between protein expression which
yield paradoxically similar luciferase activities in HeLa and HT1080 cells indicates that
this is likely not the completely correct interpretation. In support of this statement, when
either cell line is transfected with 1.9μg of pcDNA3-HA-hDREF, there is a significant
decrease in luciferase activity compared to the control, whereas hDREF expression is
higher. If negative auto-regulation of hDREF was the complete explanation for the
observed changes in transcription, trans-activation should not have been reduced below
background control levels in HeLa cells.
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Perhaps in addition to negative auto-regulation at the genomic level, a molecular switch
occurs in the hDREF protein at a certain expression threshold, which changes it from a
transcriptional activator to a transcriptional repressor. Recently it has been found that
dDREF can recruit the chromatin remodelling complex XNP/dATRX to repress
transcription of several transcription factors including dE2F (273). Thus it seems entirely
possible as well as intriguing, that hDREF can both activate and repress transcription at a
single hDRE in a concentration dependent manner. Indeed many transcription factors
display dual activator and repressor functions. Their activities are usually controlled by
external factors. For example, the Sp3 transcription factor functions as an activator,
unless SUMOylated by SUMO (small ubiquitin-related modifier) (314). In E. coli, the
ChbR transcription factor binds a regulatory site in the chitobiose operon, which encodes
genes for transport and degradation of the chitobiose disaccharide. In the presence of
chitobiose it functions as an activator, but in the absence of chitobiose it binds the exact
same regulatory site on the operon and represses transcription (315).

The most likely reason that a decrease in trans-activation of the pGL3-H1p-Luc reporter
occurs in response to increased amounts of transfected pcDNA3-HA-hDREF is one that
is common to all other luciferase assays I performed using hDREF. At high expression
levels, hDREF may act to sequester GTFs from the hDRE promoter, or bind the GTFs
and compete for hDRE binding with hDREF that is not bound to GTFs. In addition
overexpressed hDREF may recruit the GTFs to cellular promoters instead of the reporter
plasmid. I attempted – in Figure 3.12C – to provide insight into whether the sequestration
of cellular factors was contributing to the reduced luciferase activity when high levels of
pcDNA3-HA-hDREF plasmid were transfected. I investigated sequestration effects by
increasing the amount of transfected reporter plasmid in HT1080 cells, and therefore
increasing the total potential hDREF binding sites. Similar results were observed as with
less reporter plasmid, however I utilized a smaller number of transfection conditions and
therefore may have overlooked the amount of transfected pcDNA3-HA-hDREF plasmid
required to observe significant trans-activation.
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Interestingly, the raw output of light units as read by the luminometer in the sample
containing only the reporter increased from around 5x105 to 5x106 when I increased the
amount of pGL3-H1p-Luc reporter from 0.1 to 1.0μg in HT1080 cells. Additionally, in
HeLa cells, the raw output of light units in the sample containing 0.1μg of reporter only
was around 6x106. As evidenced by Figure 3.7, HeLa cells express higher levels of
endogenous hDREF relative to HT1080 cells. Taken together these results indicate that
the endogenous levels of hDREF in both HT1080 and HeLa cells are likely so high that
all of the transfected pGL3-H1p-Luc reporter plasmid – which contains only a single
hDRE element – became saturated with excess endogenous hDREF in my experiments. If
correct, this finding alone would preclude the ability to detect major differences in transactivation when varying amounts of exogenous plasmid encoding HA-hDREF are
transfected. The majority of exogenous hDREF would then act in a negative fashion to
compete for GTFs and thereby reduce basal levels of transcription below samples
expressing only the reporter. In addition, this would explain why other researchers and I
have only detected minor levels of transcriptional activation by hDREF using transient
luciferase assays in these two cell lines (285, 292). In retrospect, the use of IMR-90 cells
– which express the lowest amount of endogenous hDREF out of the four cell lines I
tested – would have been a more appropriate cell line choice for all luciferase assays.
However, their slow rate of replication and low levels of transcription and protein
synthesis might restrict the use of luciferase assays. To enable the use of HT1080 and
HeLa cells, in my opinion, a useful future experiment would be to engineer luciferase
reporter plasmids which contain only a minimal promoter and a single hDRE site. If
hDREF truly activates from the hDRE, then transfecting increasing amounts of this
specific plasmid would be expected to increase luciferase activity until the point that
endogenous hDREF is no longer present in excess with respect to the reporter plasmid.
This would also remove many confounding factors from the system, as the pGL3-H1pLuc reporter contains the full length histone H1 promoter, of which the single hDRE
comprises only 10 bases of the near 550 present (285). It would also remove the need to
overexpress hDREF, which may be causing abnormal, unresolvable events to occur with
respect to hDREF-induced transactivation. However, these experiments would also
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require the construction of negative control luciferase reporter which was otherwise
identical except for a mutated hDRE that was unable to bind hDREF.

4.3
The Effects of hDREF on Viral Early Gene and
Cellular Gene Transcription during HAdV-5 Infection
Using quantitative RT-PCR experiments in HeLa cells infected with HAdV-5 mutants at
an MOI of 5 PFU per cell, I have shown that hDREF plays a significant role in the
activation of the HAdV-5 E3 and E4 genes. In addition, a 40% knockdown of hDREF
does not affect activation of the early region E2 gene, or the histone H1 and RPS6
cellular genes. The majority of HAdV-5 infection studies in HeLa cells have been carried
out at an MOI of 10 or higher, whereby early gene expression begins around 1 hour after
infection and DNA replication begins after ~6 hours (75). Each early gene displays
different transcriptional kinetics. E3 and E4 transcripts reach maximal transcription
around 3 to 4 HPI, and decline over the next 6 hours. Not surprisingly, the E2 transcripts
are the last to be expressed, beginning at 2 HPI, reaching maximal transcription at 7 HPI,
and then declining. Since I previously detected strong expression of E1A at 12 HPI in
HeLa cells infected at an MOI of 5, and showed that an interaction between hDREF and
E1A can occur in these cells, I chose to perform quantitative RT-PCR experiments using
an MOI of 5 as well. Without any published record of the kinetics of HAdV-5 early gene
expression in HeLa cells at this MOI, I had to make an educated guess as to what time
points to use. I decided to examine gene expression at 6 and 10 HPI, operating under the
assumption that half as much virus per cell would yield 50% slower infection kinetics.
My results display trends similar to transcription kinetics at an MOI of 10, as E3 and E4
transcripts are detectable at 6 HPI, and are present at increased levels at 10 HPI.
Furthermore, E2 transcripts are delayed, and are detectable only at 10 HPI.

The most significant result of this experiment is the detection of hDREF involvement in
early gene E3 and E4 transcription; however, other results deserve individual mention as
well. First, hDREF appears to have no effect on E2 transcription. This may be explained
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by the fact that the E2 gene is trans-activated in an E1A- independent manner by the
E4orf6/7 protein, which recruits E2F to its respective binding sites in the E2 promoter
(149, 150). Second, and quite surprisingly, there were also no significant differences in
the levels of histone H1 and RPS6 transcripts when hDREF was knocked down. Based on
the results of previous researchers and myself, one would expect that since hDREF is a
weak trans-activator of both of these genes, at least a small reduction in their
transcription would result from hDREF knockdown. This could be the result of an
incomplete knockdown. Thus, even with a 40% reduction of hDREF, there still may be
sufficient hDREF in the cell to trans-activate genes intimately required for the cell cycle
and protein metabolism, such as histone H1 and RPS6 (292, 295). With further
optimization of the protocol, it may be possible to achieve close to 100% knockdown of
hDREF in HeLa cells, which could resolve this potential issue. In support of this, the
histone H1 mRNA levels at 10 HPI, and the RPS6 mRNA levels at 6 and 10 HPI are
slightly decreased in the hDREF knockdown samples. Finally, E1A may play a weak role
in trans-activation of the histone H1 and RPS6 genes. Figure 3.14 displays results as fold
activation of genes in dl309 (WT E1A) infected samples relative to dl343 (non-functional
E1A) infected samples. If E1A has no effect on a specific gene, the relative fold
activation remains at or around a value of 1. Therefore, relative fold activations above
one indicate a role of E1A in transcription of the respective genes during infection, as
dl343 encodes a non-functional E1A. The relative fold activations of histone H1 at 6 HPI,
and RPS6 at 6 and 10 HPI are all above one, implicating E1A in their trans-activation.

It is important to note that although my results show that hDREF affects viral E3 and E4
transcription, and E1A may affect cellular histone H1 and RPS6 expression, the
conclusion that these effects are mediated by the E1A-hDREF interaction cannot yet be
made. It is entirely possible that hDREF is affecting viral E3 and E4 transcription
independently of its interaction with E1A, and vice versa for cellular genes. However,
based on the previous data which shows that E1A interacts with hDREF, a logical
hypothesis is that E1A recruits hDREF to early viral promoters and hDREF recruits E1A
to the histone H1 and RPS6 promoters. To properly address this question, creation and
testing of an HAdV-5 derivative which expresses a mutant form of E1A deficient in
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hDREF binding could be performed as discussed in section 4.1. If the results of my
experiments can truly be attributed to the E1A-hDREF interaction, then such a mutant
virus would yield quantitative RT-PCR results displaying similar trends to when hDREF
was knocked down. Furthermore, to determine whether hDREF and E1A are co-localized
to the promoters of the E3, E4, and potentially histone H1 and RPS6 genes, a future
experiment would be to perform ChIP experiments. ChIP experiment are powerful tools,
and recently our laboratory has used ChIP experiments to show that E1A sequesters
hBre1 from cellular genes, and recruits it to early viral genes to enhance their
transcription (214, 215).

To better understand how hDREF may be enhancing transcription of several early viral
genes, I searched the HAdV-5 genome for hDRE-like sequences. Interestingly, two
hDRE-like sequences which match 8 of 10 consensus bases of the hDRE exist
downstream of the E4 gene at around 34,000 base pairs; one exists at around 1450 base
pairs which is upstream of the E1B gene. Not surprisingly, these sites are conserved in
other members of species C, which share around 99% genomic identity. These sites are
also conserved in several simian adenoviruses (SAdVs) closely related to species C, such
as SAdV-34, 40.2, 40.1, 42.1, 42.2, and 42.3 which are all about 88-96% similar to
HAdV-5 in genomic sequence. These sites however are not found in conserved locations
for the less related HAdVs such as 12, 3, 9, 4, and 40, which share about 80% genomic
conservation with HAdV-5. Interestingly, HAdV-12, and 3 contain an hDRE-like
sequence matching 9 of 10 consensus bases of the hDRE centered around 10,000 base
pairs into the genome. This region is upstream of the major late promoter. Perhaps
different subgroups have evolved to utilize hDREF to enhance expression of distinct viral
genes. Although the two hDRE elements found near the E4 gene are downstream of the
TSS, they may still function as hDREF binding and trans-activation sites. This would
serve to provide a reasonable explanation as to why E4 transcription appears highly
responsive to hDREF. Indeed, trans-activators have been shown to enhance
transcriptional activation via enhancers located thousands of bases away, whether
upstream or downstream of the promoters they act on (316, 317). Importantly, there may
be hDRE-like sequences near the E3 transcriptional unit promoter as well, as my
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preliminary scan of the HAdV-5 genome using Clustal-W algorithms may have
overlooked more divergent sequences. Finally, my experiments did not look at the effects
of hDREF on early gene E1B expression, which was also found to contain an hDRE-like
element upstream of the TSS. Thus, E1B expression is an important candidate to monitor
in future experiments examining the effects of hDREF on early viral gene transcription.

4.4

The Effects of hDREF on HAdV-5 Replication

The replicative cycle of HAdV-5 experiences vastly delayed kinetics in contact-inhibited
IMR-90 cells in comparison to HeLa cells. For example, previously published
experiments that examined viral growth in IMR-90 cells were performed at an MOI of 5
PFU per cell, and virus was collected at 4, 48, and 120 HPI (77, 78). I decided to emulate
these experimental conditions. The results of plaque assay experiments from HAdV-5
mutants isolated from IMR-90 cells indicate a significant 1.8 fold decrease in dl309 viral
titre at 120 HPI when hDREF is approximately 100% knocked down. Similar to the
scenario in section 4.3, these differences cannot be attributed directly to the interaction of
E1A and hDREF without performing plaque assay experiments using HAdV-5 mutants
encoding E1A which does not bind hDREF. Such a mutant would be predicted to display
identical growth characteristics regardless of whether hDREF was knocked down or not.
No differences were observed in dl309 titre from viruses collected at 4 or 48 HPI. I did
not expect any differences at 4 hours, as no E1A was present at this time, and even in
HeLa cells, viral DNA replication does not begin until 6 HPI at an MOI of 10 (75). The
viral titre of dl309 infected samples only increased minimally by a factor of 2 between 4
and 48 HPI, whereas titres increased by over 10 fold between 48 and 120 HPI (Data not
shown). Therefore, minimal viral replication had occurred in dl309 samples after 48
hours, regardless of the status of hDREF. Accordingly, it is not surprising that no
differences in viral titre were observed between hDREF siRNA and scramble siRNAtreated samples at 48 HPI.
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As expected, dl312 titres remained constant across all time points, indicating the inability
of this virus to replicate without E1A, regardless of the presence or absence of hDREF.
One final observation can be made; hDREF does not have an effect on E1A expression,
as the levels of E1A at individual timepoints between hDREF siRNA and scramble
siRNA-treated samples are similar. Therefore, in contrast to what was shown with E3 and
E4 genes, hDREF likely does not affect E1A gene transcription. Future experiments
should examine viral replication at time points between 48 and 120 HPI, as well as time
points after 120 HPI. This would elucidate when the levels of replication start to diverge,
and whether or not the growth defect seen in hDREF siRNA-treated samples remedies
itself at later time points, or becomes further amplified.

Studies of the effects of hDREF on S phase progression in HAdV-5 infected contactinhibited IMR-90 cells were also performed, utilizing a dual propidium iodide staining
and bromodeoxyuridine incorporation protocol described by Cecchini et al. (318). The
expression of hDREF has previously been shown to influence cell cycle progression, and
is necessary for entry into S phase (285, 292). Therefore, the goal of these experiments
was to examine whether knockdown of hDREF in HAdV-5 infected IMR-90 cells
reduced S phase progression, or whether HAdV-5 could compensate for the lack of
hDREF during infection. Based on the plaque assay results, I did not expect to see major
differences in cell cycle progression at 4 or 48 HPI, but expected to observe differences at
120 HPI. In fact, no noticeable differences at 4, 48 or 120 HPI between hDREF siRNA
and scramble siRNA treated samples were observed. However, due to inherent
complications in these experiments, the data is not shown, and cannot be properly
interpreted. HAdV-5 is a lytic virus, and therefore at 120 HPI, the majority of cells are
lysed and cannot be properly assayed for DNA content by a flow cytometer. In the future,
transfection based experiments may be required to examine how the E1A-hDREF
interaction affects S phase progression. E1A which is sufficient or deficient for hDREF
binding could be transfected into contact-inhibited IMR-90 cells treated with either
hDREF siRNA or scramble siRNA, and subsequently the dual staining and incorporation
protocol could be utilized.
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4.5

Summary of Findings and Future Directions

My thesis project has revealed several interesting findings with regards to the functions
of the poorly characterized hDREF protein. I have identified that there is an interaction
between 13S E1A and hDREF, which is conserved amongst representative serotypes of
HAdV species A through E – HAdV 12, 3, 5, 9, and 4 respectively – but not HAdV-40 of
species F. In addition, all five isoforms of HAdV-5 E1A – 13S, 12S, 11S, 10S, and 9S –
can bind hDREF. Amino acids 15-26 of E1A are sufficient for E1A to interact with
hDREF, however other residues may contribute to binding. Therefore, a future direction
of the project is to identify all residues essential for hDREF binding, in order to mutate
them and generate a HAdV-5 derivative encoding an E1A mutant deficient for hDREF
interaction. In addition, it would be interesting to identify factors which coimmunoprecipitate in complexes with hDREF and observe whether the identities of
factors in these complexes are altered in the presence of E1A. These studies may help to
identify currently unknown cellular binding partners of hDREF.

Consistent with previously published results, hDREF appears to be a weak trans-activator
at the histone H1 promoter (285). However, it may repress transcription at this promoter
as well, through an unknown mechanism. In addition, hDREF does not possess the
capability to trans-activate at a minimal promoter containing only a TATA box. Finally,
when large amounts of pcDNA3-HA-hDREF plasmid are co-transfected with plasmids
encoding Gal4-DBD-tagged AA1-82 or CR3 of E1A, the abilities of these known transactivators to drive luciferase expression through a minimal promoter are significantly
reduced. The probable inherent flaws of my luciferase assay experimental design, as well
as how to alleviate their issues for future experiments were addressed in detail in section
4.2. Further examination of hDREF’s function as a trans-activator is warranted. Potential
solutions involve carrying out the same experiments in different cell lines which express
less endogenous hDREF, or utilizing HT1080 and HeLa cells without overexpressing
exogenous HA-hDREF. In addition, to truly examine whether hDREF can transactivate
through the hDRE, a reporter plasmid should be engineered which contains only a
minimal promoter and an upstream hDRE.
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I have shown that either directly or indirectly, hDREF plays a significant role in the
activation of HAdV-5 early region E3 and E4 genes during infection. As well, E1A may
be involved in histone H1 and RPS6 trans-activation during infection. Future directions
may include examining the effects of hDREF on all viral early genes during infection
when close to 100% knockdown of hDREF is achieved. In addition, once a mutant virus
is created which expresses E1A deficient for hDREF binding, it will be possible to
determine whether the observed effects are due to the E1A-hDREF interaction, or to
some other unknown activity of hDREF in the cell. Finally, ChIP experiments examining
whether E1A and hDREF co-localize to early viral promoters or cellular H1 and RPS6
promoters would provide support to my data.

Lastly, I have shown that hDREF plays a significant role in HAdV-5 replication in
quiescent, contact-inhibited IMR-90 cells. Future experiments should examine viral titres
from 48 to beyond 120 HPI in order to generate a viral growth curve with respect to the
presence or absence of hDREF. Finally, once a mutant virus is created which expresses
E1A deficient for hDREF binding, it will be possible to determine whether the observed
effects on viral replication are due to the E1A-hDREF interaction, or to some other
function of hDREF during infection.

My original hypothesis was that the interaction between E1A and hDREF contributes to
adenovirus induced transcriptional modulation and viral replication in HAdV-5 infected
cells. Although I can’t conclusively say whether the E1A-hDREF interaction is
contributing to the observed effects, it is clear that my data demonstrates that hDREF
contributes to adenovirus early gene transcription and viral replication in HAdV-5
infected cells. Future experiments should determine whether the interaction is responsible
for my observed results. Based on all of my observed results, I have synthesized a model
which outlines the potential consequences of the E1A-hDREF interaction in an HAdV-5
cell (Figure 4.2).
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Figure 4.2 Cartoon diagram of the potential effects of the E1A-hDREF interaction
in an HAdV-5 infected cell. Green arrows within circles represent increases in gene
expression or viral replication respectively. Question marks within circles represent the
unknown or potential effects of hDREF or E1A on genes which warrant further
investigation. hDREF increases expression of E3 and to a greater degree, E4. hDREF also
increases HAdV-5 replication. hDREF may affect E1B expression through a putative
hDRE-like sequence found upstream of the E1B gene. E1A may enhance histone H1 and
RPS6 gene expression. The question mark between E1A and hDREF indicates that
although E1A and hDREF have been shown to interact, the effects of hDREF on viral
gene expression and viral replication have not been directly linked to this interaction.
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Figure 4.2 Cartoon diagram of the potential effects of the E1A-hDREF interaction
in an HAdV-5 infected cell
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